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INTRODUCTION 
Bacterial ribosomes represent one of the most important targets for antibiotics 
in the cell and several larger and smaller classes of protein synthesis inhibitors 
have been discovered or designed. Many years of biochemical and structural 
studies have revealed the molecular basis by which antibacterial compounds 
inhibit translation. Tetracyclines and most of aminoglycosides bind to the 
decoding site of the 30S ribosomal subunit and interfere with its ability to 
decipher the genetic information encoded in the mRNA. The 50S subunit has 
three major antibiotic binding sites. One of them is the peptidyl-transferase 
centre (PTC) where the peptide bond is being catalyzed between the growing 
polypeptide chain attached to the peptidyl tRNA and the amino acid on the 
incoming aminoacyl-tRNA. Antibiotics such as phenicols, oxazolidinones, 
tiamulin and streptogramin A interfere with the binding of tRNA into the PTC 
or inhibit peptide bond formation. The second prominent target site on the 50S 
subunit is the protein exit tunnel. The tunnel serves as a binding site for 
macrolides, lincosamides and streptogramin B antibiotics. These drugs inhibit 
protein synthesis by interfering with the progression of the nascent peptide. 
Another target for antibiotics is the GTPase-associated region that provides a 
docking site for elongation factors and coordinates GTP hydrolysis during 
protein synthesis. This region acts as a binding site for the thiopeptide anti-
biotics such as thiostrepton. Considering the chemically large diversity of anti-
biotics, they target the ribosome at surprisingly few locations. 
Protein synthesis can be divided into four distinct phases (initiation, elon-
gation, termination and recycling). Regulation of translation occurs largely at 
the level of initiation and is often accomplished by small proteins or RNA mole-
cules that bind to the mRNA. However, in some cases translation is regulated 
via nascent polypeptide-mediated ribosome stalling. This regulation mechanism 
may require the presence of a small ligand molecule that specifically interacts 
with the nascent peptide inside the ribosomal exit tunnel. The first part of my 
experimental work describes a novel method for selecting peptides capable of 
inhibiting translation in response to different chemicals. We believe that applying 
our method on a larger scale could contribute to identification of the sequence 
rules underlying the activity of cis-acting regulatory peptides. In addition, this 
method might be applicable in the development of novel gene expression 
systems. 
Since their discovery in the 1930s, antibiotics have saved a countless number 
of lives. However, recent years have seen events that are more characteristic to 
the pre-antibiotic area. The most well-known problem is the spread of drug-
resistant “superbugs”. It is very likely that resistance to even a new class of anti-
biotics will be observed already within a few first years of marketing. Genes 
encoding components of resistance machinery are often located on mobile 
genetic elements and can be transferred between bacteria via horizontal gene 
transfer. Bacteria use a great variety of mechanisms to achieve resistance to 
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antibiotics. Among these, ribosomal protection represents a unique tactics for 
promoting tetracycline resistance. Ribosomal protection proteins are known for 
their ability to dislodge tetracycline from the ribosome. The second part of my 
experimental work explores the molecular mechanism of this important type of 
resistance.  
As the emergence and spread of multidrug-resistant pathogens continues to 
be one of the major public health concerns, the development of new anti-
microbials has become an important issue. While 30 new antibiotics have been 
launched worldwide since the year 2000 and many promising drug candidates 
are currently in clinical trials, development of many compounds has been dis-
continued due to different reasons. On the other hand, some antimicrobial agents 
are used clinically, although their mechanism of action is still a matter of 
debate. An example of such drugs is the putative translation inhibitor nitro-
vinylfuran G1 (or Furvina®) that is already many years medically used in Cuba. 
The third part of my experimental work focuses on aspects concerning anti-
bacterial activity and stability of G1 compound. 
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1. REVIEW OF LITERATURE 
1.1. Major classes of bacterial translation inhibitors 
Antibiotics possess three main targets or pathways in bacteria: the ribosome, 
cell wall synthesis and DNA gyrase or DNA topoisomerase. The current thesis 
focuses on antibiotic classes that target the bacterial ribosome and interfere with 
microbial protein synthesis.  
Ribosomes are macromolecular machines that convert the genetic infor-
mation encoded in the messenger RNA into proteins. Considering the essential 
function of protein synthesis, it is not surprising that this process is a target for 
many antibacterials. The majority of translation inhibitors affect the translation 
elongation cycle. Nevertheless, almost every step of bacterial protein synthesis 
can be inhibited with antibiotics (Wilson, 2009). Many translation inhibitors are 
clinically important drugs. 
 
Figure 1. Antibiotic binding sites on 30S and 50S ribosomal subunits. The figure is 
adapted and modified from Poehlsgaard and Douthwaite (2005). 
 
 
1.1.1. Tetracyclines 
Tetracyclines (Figure 2) are known as historically first described group of anti-
biotics possessing broad-spectrum antibacterial activity. In addition to inhibiting 
growth of Gram-positive and Gram-negative bacteria, they are also active against 
mycobacteria, spirochetes, and malaria-causing protist Plasmodium falciparum. 
First reported tetracyclines were chlortetracycline and oxytetracycline, pro-
duced by soil bacteria Streptomyces aureofaciens and Streptomyces rimosus, 
respectively. Chlortetracycline was discovered in 1948 by Benjamin Duggar 
(American Cyanamid) while oxytetracycline was isolated in the early 1950s by 
Alexander Finlay (Pfizer) (Duggar, 1948; Finlay et al., 1950). After the chemical 
structures of both antibacterials were solved in 1953, the Pfizer chemists 
Thiostrepton
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Streptogramin A,
chloramphenicol,
puromycin
Tiamulin
Macrolides
Streptogramin B,
lincosamides
Spectinomycin
Tetracycline
Pactamycin
Hygromycin B
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geneticin
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chemically modified chlortetracycline and generated an antibiotic tetracycline. 
However, tetracycline was soon found also from spent broth of both S. 
aureofaciens and S. rimosus (Backus et al., 1954; Perlman et al., 1960). Sub-
sequent studies revealed that tetracycline is a precursor of chlortetracycline 
(McCormick et al., 1960). 
 
 
Figure 2. Chemical structures of tetracycline antibiotics. 
 
The era of second-generation tetracyclines started with the emergence of semi-
synthetic tetracycline derivatives. The most well-known semisynthetic tetra-
cyclines doxycycline and minocycline were introduced in 1967 and 1972, 
respectively (Chopra and Roberts, 2001). The semisynthetic analogs appeared 
to be more lipophilic, thus being able to penetrate bacterial cell membranes more 
efficiently. They also demonstrated improved antimicrobial activity, higher 
affinity to the ribosome and decreased toxicity (Nguyen et al., 2014). Never-
theless, the importance of tetracyclines in human medicine started to diminish 
mainly because of the rise of antibacterial resistance, and the appearance of 
more effective drugs. Still, in 2006, tigecycline was approved by FDA and 
became clinically available. Tigecycline is classified as a member of third-
generation tetracycline family, also known as glycycyclines (Peterson, 2008). 
The glycycyclines bear N,N-dimethylglycylamido moiety at the C9 position of 
carbocyclic skeleton. They are promising drugs because they have improved 
ribosome binding properties and they retain activity against some bacterial strains 
that contain tet resistance genes (Bauer et al., 2004., Bergeron et al., 1996). Two 
additional glycycyclines, omadacycline and fully synthetic eravacycline, are 
currently in Phase III clinical trials (Sun et al., 2015).  
Tetracyclines are structurally similar as they all contain a 19-carbon four-
ring cyclic skeleton. The members of tetracycline family differ from each other 
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by the structural variations, which mainly affect the C5, C6 or C7 carbons of the 
molecule. The naphthacene core of tetracyclines is formed from a starter molecule 
acetyl-CoA. Ketosynthase and other enzymes are responsible for the iterative 
condensation of 8 molecules of malonyl-CoA to yield the polyketone backbone 
of tetracycline (Pickens and Tang, 2009). 
Members of tetracycline family may be divided into two classes according to 
their mode of action: (1) “typical” tetracyclines (e.g. oxytetracycline and mino-
cycline), which are bacteriostatic and inhibit prokaryotic protein synthesis, and 
(2) “atypical” tetracyclines (e.g. chelocardin and 6-thiatetracycline), which 
interfere with electrochemical gradient of the bacterial cell membrane and induce 
cell lysis, thus being bactericidal. 
The crystal structures of tetracycline in complex with the Thermus ther-
mophilus 70S ribosome and with the 30S ribosomal subunit revealed that the 
binding site of the drug is located near the A-site where it partly overlaps with 
the anticodon stem-loop of the tRNA (Brodersen et al., 2000; Jenner et al., 
2013; Pioletti et al., 2001). The binding pocket of tetracycline is formed by the 
irregular minor groove of helix 34 of 16S rRNA (rRNA residues 1054–1056 
and 1196–1200; Escherichia coli base numbering is used throughout) in 
combination with residues 964–967 of helix 31 of 16S rRNA. The lower 
peripheral region of tetracycline molecule forms hydrogen bonds with the sugar-
phosphate backbone of rRNA residues that constitute the binding pocket. The 
contacts are therefore sequence-independent, thus explaining the broad-spectrum 
activity of the drug. The binding of tetracycline to the ribosome is coordinated 
through a magnesium ion that facilitates interaction with the phosphate back-
bone of helix 34 (White and Cantor, 1971; Brodersen et al., 2000). It has been 
proposed that another magnesium ion mediates the interaction between the 
phosphate backbone of G966 in helix 31 and the ring A of tetracycline (Jenner 
et al., 2013). Tigecycline has been shown to bind 30S subunit analogously to 
tetracycline (Jenner et al., 2013). 
Tetracyclines are inhibitors of translation elongation cycle. In the presence 
of tetracycline, aminoacyl-tRNA:EF-Tu:GTP ternary complex is still able to 
bind the ribosome. Tetracycline does not interfere with codon-anticodon inter-
action and GTP hydrolysis by EF-Tu (Brodersen et al., 2000; Gordon, 1969). 
However, tetracycline blocks progression of aminoacyl-tRNA from the initial 
codon recognition state to the A-site of the ribosome (Blanchard et al., 2004). 
As a result, aminoacyl-tRNA is prematurely released and the elongation cycle 
terminates without peptide bond formation. Tetracyclines can make protein 
synthesis energetically expensive for cells, as GTP hydrolysis by EF-Tu occurs 
without peptidyl transfer (Brodersen et al., 2000). 
In addition to the primary binding site, biochemical and X-ray crystallo-
graphy studies have revealed five other tetracycline binding sites at different 
locations on the head and the body of 30S subunit (Oehler et al., 1997; Pioletti 
et al., 2001). According to current knowledge, these secondary binding sites are 
not involved in translation inhibitory mechanism as resistance to the drug has 
13 
been shown to occur through mutations of nucleotides within the primary 
binding site (Gerrits et al., 2002). 
Resistance to tetracyclines can be conferred by the unique ribosome pro-
tection proteins, such as Tet(M) and Tet(O). Membrane-bound efflux proteins, 
including Tet(A), Tet(B), Tet(K) and Tet(L) can similarly be responsible for the 
resistance. Alternative resistance mechanisms involve mutations in 16S rRNA 
as reported in Helicobacter pylori and inactivation of the drug by hydroxyase 
Tet(X) (Wu et al., 2005; Yang et al., 2004). 
 
 
1.1.2. Aminoglycosides 
Aminoglycosides (Figure 3) are active against many aerobic Gram-negative and 
Gram-positive pathogens, including Klebsiella pneumoniae, Yersinia pestis and 
Haemophilus influenza. These drugs are also efficient for curing infections 
caused by Pseudomonas and Acinetobacter that are not effectively treatable with 
other antibiotics. It is a common practice to use aminoglycosides in combination 
with other antibiotics in order to reduce microbial resistance. They are poorly 
absorbed via the gastrointestinal tract and, thus, are preferably administered via 
the intramuscular or intravenous route (Craig 2011). Inhaled delivery of amino-
glycosides has become an area of renewed interest and inhaled tobramycin is 
available in the European Union. Aminoglycosides are bactericidal, which is 
uncommon among antibiotics acting as inhibitors of protein biosynthesis. 
The first member of aminoglycoside group was isolated in 1943 by Albert 
Schatz who was working in Selman Waksman’s laboratory at Rutgers Uni-
versity. It was a fermentation product of Streptomyces griseus, hence the name 
streptomycin (Schatz et al., 1944). Streptomycin was the first antibiotic that was 
successfully used to cure tuberculosis. Intensive research leaded to the discovery 
of other natural aminoglycosides, such as neomycin (1949), kanamycin (1957), 
gentamicin (1963) and tobramycin (1967). The spread of microbial resistance to 
aminoglycosides and their obvious toxicity were the ground for improving phar-
macological profile of aminoglycosides. These efforts led to introduction of 
semisynthetic derivatives in 1970s. Amikacin (1972), arbekacin (1973) and 
isepamicin (1975) are some examples of these second-generation aminoglyco-
sides. 
Naturally occurring aminoglycosides are products of secondary carbohydrate 
metabolism. They are mostly produced by the genuses Streptomyces and Micro-
monospora and carry suffixes “-mycin” or “-micin”, respectively. An exception 
is butirosin, which is produced by Bacillus circulans (Woo et al., 1971). 
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Figure 3. Structures of representative aminoglycoside antibiotics.  
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Aminoglycosides can be divided into 3 families according to their chemical 
structure.  
 
(1) 4,5-disubstituted-2-deoxystreptamines 
 
Their molecule contains an aminocyclitol 2-deoxystreptamine (DOS), which is 
disubstituted at C4 and C5 positions. Members of this family can be either 
pseudotrisaccharides (butirosin, ribostamycin) or pseudotetrasaccharides (neo-
mycin, lividomycin, paromomycin).  
 
(2) 4,6-disubstituted-2-deoxystreptamines 
 
This aminoglycoside family is clinically most widely used. These drugs contain 
sugars at C4 and C6 positions of DOS. Gentamicin, kanamycin, tobramycin and 
amikacin are prominent members of this family. They are further divided into 
groups based on their sugar substituents. 
 
(3) Non-2-deoxystreptamine aminoglycosides 
 
These molecules contain an aminocyclitol other than 2-deoxystreptamine. Well-
known members of this group are streptomycin and its derivatives. The mole-
cule of streptomycin can be categorized as a pseudotrisaccharide. It contains a 
6-carbon aminocyclitol called streptidine. Sugar derivatives pentose (L-strep-
tose) and glucosamine are linked to aminocyclitol ring via glycosidic bonds. 
 
Up to date, a number of aminoglycosides have been crystallized in complex 
with 70S ribosome, 30S ribosomal subunit or small RNA fragments mimicking 
helix 44 of 16S rRNA. Aminoglycosides are a large group of antibiotics whose 
members display diversity in binding to the target as well as in their mechanism 
of action. Aminoglycosides have been shown to inhibit translational fidelity 
(streptomycin, paromomycin, geneticin), translocation (hygromycin B) and also 
ribosome recycling (gentamicin, neomycin). 
The most studied mechanism of aminoglycoside action is the effect on the 
accuracy of translation. Aminoglycosides, such as paromomycin and geneticin, 
interact with the 16S rRNA helix 44 that is located within the A site of 30S 
ribosomal subunit (Vicens and Westhof, 2001). This region comprises the 
decoding center of the ribosome and functions by monitoring the formation of 
correct interaction between mRNA codon and tRNA anticodon. Two uni-
versally conserved nucleotides of helix 44, A1492 and A1493, are crucial for 
this process. A cognate codon-anticodon interaction induces a conformational 
change accompanied by the flip-out of A1492 and A1493. This event in turn 
induces other rearrangements inside the ribosome that lead to tight codon-
anticodon interaction (Nierhaus, 1993). When aminoglycosides bind into A-site, 
their amino-sugar rings interact with helix 44 and force A1492 and A1493 to 
flip outside (Vicens and Westhof, 2001; Vicens and Westhof, 2003). As a 
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result, the decoding center adopts a conformation that allows the binding of 
noncognate tRNAs to the A-site. Therefore, incorrect amino acids can be 
incorporated to growing polypeptide chain. Mistranslated proteins insert into 
and cause damage to the cytoplasmic membrane. This leads to rapid uptake of 
additional aminoglycoside molecules that in turn increase mistranslation (Davis 
et al., 1986). It has been estimated that normally the ribosome is responsible for 
one misreading for every 1000 – 10,000 correct amino acids (Zaher and Green, 
2009). Aminoglycosides can decrease translation fidelity down to one mis-
reading for 100 amino acids (Wilson, 2009). 
Streptomycin binds to a distinct site near the A-site and makes contacts with 
16S rRNA helices 1, 18, 27 and 44 as well as with the ribosomal protein S12 
(Carter et al., 2000). The binding of the drug induces a lateral shift of decoding 
region of helix 44, thereby causing translational misreading by a mechanism 
unrelated to other aminoglycosides (Demirci et al., 2013). Streptomycin alters 
the rate by which GTP hydrolysis occurs during the selection of aa-tRNA in the 
A-site. Normally, GTP hydrolysis by EF-Tu is very fast for cognate codon-
anticodon complexes and slower for near-cognate complexes. Streptomycin has 
been shown to reduce the rate of GTPase activation for cognate codons and 
increase the rate of GTPase activation for near-cognate codons, resulting in 
reduction of selectivity (Gromadski and Rodnina, 2004). 
In contrast to paromomycin and geneticin, the binding of hygromycin B to 
helix 44 induces the flip-out of A1493 alone. In this position, A1493 would 
block the movement of tRNAs between the A and P sites (Borovinskaya et al., 
2008). Hygromycin B effectively inhibits translocation in both bacteria and 
eukaryotes (Eustice and Wilhelm, 1984).  
Studies of X-ray crystal structures of E. coli 70S ribosome revealed that 
aminoglycosides, such as gentamicin and neomycin, possess an additional 
binding site located at 23S rRNA helix 69. Indeed, these drugs interact with the 
region that overlaps the binding site of ribosome recycling factor. Therefore, 
binding of aminoglycosides to 50S subunit interferes with the release of ribo-
somes from mRNA and inhibits recycling of ribosomes (Borovinskaya et al., 
2007). 
The use of aminoglycosides in human medicine is complicated because of 
their adverse effects. Nephrotoxicity, ototoxicity and neuromuscular blockade 
are most serious problems to the patients. It has been shown that nucleotides 
A1408 and G1491 of prokaryotic 16S rRNA are essential for aminoglycoside 
binding (Francois et al., 2005). Human mitochondrial rRNA contains adenine 
and guanine at the same positions, which can provide some explanation for 
aminoglycoside toxic side effects (Hobbie et al., 2008). 
Enzymatic modifications of drug molecule contribute the major resistance 
mechanism to aminoglycosides. Mutations in helix 44 and genes encoding 
ribosomal proteins S12 and S5 can also confer resistance. Some efflux systems 
are involved in moderate resistance to aminoglycosides (Moore et al., 1999). 
Many natural aminoglycoside producers protect themselves by having methyl-
transferases that methylate residues A1405 and A1408 of 16S rRNA (Cundliffe, 
17 
1989). Recently, several plasmid-borne methyltransferases have emerged in 
clinical isolates that show high-level resistance to many aminoglycosides 
(Krause et al., 2016). 
 
 
1.1.3. Macrolides 
Macrolides (Figure 4) represent a large and clinically important class of anti-
biotics. They inhibit the growth of many Gram-positive and certain Gram-
negative bacteria. On the other hand, their activity against Enterobacteriaceae 
and Pseudomonas spp is weak. First macrolides were isolated in the early 1950s. 
First, pikromycin was discovered in 1950 (Brockmann and Henckel, 1951). 
Erythromycin was found shortly thereafter from the fermentation broth of acti-
nomycete Saccharopolyspora erythraea (formerly known as Streptomyces 
erythreus) (McGuire et al., 1952). 
All medically used macrolides comprise either 14-, 15- or 16-membered 
macrolactone ring to which certain saccharide molecules are attached. Mole-
cules possessing smaller or larger lactone ring tend to exhibit weak antibacterial 
activity. 
Erythromycin A is considered the prototype of 14-membered macrolides. The 
molecule of erythromycin consists of 14-membered lactone with desosamine 
and L-cladinose linked to C5 and C3 position, respectively. Other well-known 
naturally occurring 14-membered macrolides are oleandomycin, lankamycin 
and megalomicin. Semi-synthetic members of this group include clarithromycin 
and roxithromycin as well as ketolides telithromycin and cethromycin. 
The 16-membered macrolide family can be further divided into subfamilies 
according to substitution patterns of their macrolactones (Kirst, 2014). Tylosin, 
produced by Streptomyces fradiae, along with its semi-synthetic derivatives 
constitutes the first subfamily. The molecule of tylosin contains the disaccharide 
D-mycaminosy-L-mycarose at C5 and D-mycinose at C14 of the macrolactone 
ring. The second subfamily is referred as the leucomycin-spiramycin group. 
Several naturally occurring members of this group, such as josamycin and 
spiramycin are used in human medicine. 
Clinically, macrolides can be classified into three generations. The first-
generation macrolides were launched as drugs in the 1950s. Erythromycin was 
the first macrolide developed for treatment of bacterial infections in humans. 
Despite of effectiveness, the use of erythromycin in medicine encountered prob-
lems such as low oral bioavailability and low stability in acidic digestive tract. 
Development of first-generation derivatives, such as 2'-esters and acid-addition 
salts, slightly helped to reduce these difficulties.  
18 
 
Figure 4. Chemical structures of representative macrolide antibiotics. 
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The search for compounds with more favorable pharmacokinetics resulted in 
launching of semi-synthetic second-generation macrolides in the 1980s. Clari-
thromycin and azithromycin are most prominent members of this group and they 
are still widely used in medicine. Clarithromycin differs from erythromycin 
only in the 6-O-methyl group (Morimoto et al., 1984). Azithromycin contains a 
chemically expanded 15-membered macrolactone ring and the ketone group at 
the C9 position has been removed (Retsema et al., 1987). Both compounds 
demonstrated improved oral bioavailability and diminished side effects. Never-
theless, these drugs still exhibit low stability in acidic media due to the presence 
of 3-L-cladinose. 
Dramatic rise in bacterial resistance to macrolides was the main reason for 
developing novel types of macrolides. The third-generation derivatives are called 
ketolides, because their molecule contains a 3-ketone group instead of 3-cladi-
nosyl moiety. Other features of ketolides include the presence of carbamate side 
ring and the substitution at the C6 position. Ketolides like telithromycin exhibit 
improved stability in acidic environment, low propensity for selection of resistant 
mutants and stronger antimicrobial activity (Bryskier, 2000). Unfortunately, the 
use of telithromycin has been associated with rare but severe health issues 
including hepatotoxicity and visual disturbances (Kirst, 2014). The molecule of 
telithromycin has a pyridinyl-imidazolyl-butyl group linked to the C6 position 
of the carbamate ring. Cethromycin that contains a quinolinyl-allyl side chain at 
the C6 position is another promising example of ketolide family. 
Macrolides inhibit protein synthesis by impeding the progression of nascent 
peptide chain. During translation, the nascent peptide exits from the ribosome 
through a tunnel that begins near the PTC (Choi and Brimacombe, 1998). The 
tunnel wall is composed mainly of rRNA, although ribosomal proteins L4 and 
L22 also contribute in the narrowest part of the tunnel. Macrolides can bind to 
free ribosomes, but not during elongation when the exit tunnel is occupied by 
the nascent peptide (Contreras and Vazquez, 1977a). The binding site of macro-
lides is located adjacent to PTC within the tunnel where they interact with the 
23S rRNA. The prevailing view suggests that the presence of macrolide mole-
cule in the exit tunnel blocks the extension of growing polypeptide. As a result, 
the short peptidyl-tRNA dissociates from the ribosome (Menninger and Otto, 
1982). Smaller macrolides, such as erythromycin were shown to enable the 
synthesis of oligopeptides consisting of 6–8 amino acids while josamycin and 
spiramycin that penetrate deeper into exit tunnel generate shorter oligopeptides. 
Telithromycin lacks C3-cladinose and enables synthesis of 9–10 amino acids 
before peptidyl-tRNA drop-off (Tenson et al., 2003). Recent studies have 
challenged the general view of macrolide action and suggested that these drugs 
are rather protein specific translation inhibitors. It appears that some nascent 
peptides can pass through the ribosome exit tunnel even in the presence of very 
high levels of macrolides (Kannan et al., 2012). However, macrolides can arrest 
translation of the majority of polypeptides at the later stages of elongation (Davis 
et al., 2014; Kannan et al., 2014). Such translational arrest occurs at specific 
stalling sites that are located throughout the entire sequence (Davis et al., 2014). 
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New data indicate that marolides act as inhibitors of peptide bond formation 
between specific combinations of PTC donor and acceptor substrates. This 
mode of action is possibly mediated by drug-induced conformational changes in 
the PTC (Kannan et al., 2014; Sothiselvam et al., 2014). 
More than 20 crystal structures of macrolides in complex with 70S ribosome 
or 50S ribosomal subunit have been analyzed. Structure of the 50S subunit 
complexed with erythromycin revealed that the 2'OH group of desosamine sugar 
of the drug forms hydrogen bonds with nucleotides A2058 and A2059 in domain 
V of 23S rRNA (Schlunzen et al., 2001). A ketolide telithromycin has been 
crystallized in complex with ribosomes derived from eubacteria (Berisio et al., 
2003; Bulkley et al., 2010; Dunkle et al., 2010) as well as in complex with 50S 
subunit from an archaea Haloarcula marismortui bearing a mutation G2058A in 
23S rRNA (Tu et al., 2005). In all structures, the lactone ring of telithromycin is 
positioned similarly to that of erythromycin. However, variations in binding 
mode seem to exist between species due to differences in their 23S rRNA 
sequence. In the crystal structure of E. coli 50S subunit, the alkyl-aryl side-chain 
of telithromycin reaches into exit tunnel and stacks upon the A752-U2609 base 
pair (Dunkle et al., 2010). In contrast, the same side-chain is rotated by 120° 
and interacts with C2609 when bound to archaeal 50S subunit (Wilson et al., 
2005). Additional interactions with the ribosome contribute to the higher anti-
bacterial activity of ketolides. 
Studies of crystal structures of azithromycin in complex with ribosomes 
show that the binding mechanisms of macrolides possessing 14- or 15-mem-
bered lactone ring are very similar (Bulkley et al., 2010; Hansen et al., 2002). 
Interestingly, analysis of Deinococcus radiodurans 50S subunit revealed the 
second binding site for azithromycin. When bound to the second site, the drug 
interacts with ribosomal proteins L4 and L22 as well as with domain II of 23S 
rRNA (Schlunzen et al., 2003). 
The molecule of macrolides bearing 16-membered ring is larger and often 
contains disaccharides at the C5 position of the macrolide ring. Despite of larger 
size, the placement of the lactone ring and C5-sugar resembles that observed for 
erythromycin. The C14 sugar moiety of tylosin penetrates deeper into exit tunnel 
and forms additional interactions with nucleotides A748–A752 in domain II of 
23S rRNA (Hansen et al., 2002). 
A common mechanism for resistance to macrolides is modification of ribo-
somes by methylation. Methylation of 23S rRNA is accomplished by the Erm 
family of methylases. Dimethylation of A2058 in the PTC leads to steric clash 
with the C5-monosaccharide. Such methylation pattern is characteristic to so-
called MLSB phenotype, which is resistant to macrolides, lincosamides and 
streptogramin B (Weisblum, 1995a). Both A2058G and A2059G transitions 
lower macrolide affinity (Franceschi et al., 2004). Resistance to macrolides can 
also be conferred by mutations in genes encoding proteins L4 and L22, although 
there is no direct contact between these proteins and the drug. Instead, L4 and 
L22 are responsible for maintaining the 23S rRNA conformation necessary for 
macrolide binding (Gregory and Dahlberg, 1999). 
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Another mechanism of resistance is hydrolysis of macrolactone ring by 
esterases or modification of antibiotic by phosphotransferases (Arthur et al., 
1986; O’Hara et al., 1989). Efflux systems that confer resistance to macrolides 
are more common in Gram-negative bacteria, but they can also be found in 
Gram-positive cocci (Katz and Ashley, 2005). 
 
 
1.1.4. Phenicols 
Chloramphenicol (Figure 5) was originally isolated in 1947 as a fermentation 
product of a soil bacterium Streptomyces venezuelae (Ehrlich et al., 1947). It is a 
broad-spectrum antibiotic, being active against both Gram-negative and Gram-
positive bacteria as well as Chlamydiae, Rickettsiae and Mycoplasma. Although 
chloramphenicol is bacteriostatic against many bacteria, it has been shown to be 
bactericidal at clinically achievable concentrations against Haemophilus influen-
zae, Streptococcus pneumoniae, and Neisseria meningitidis (Rahal and Simber-
koff, 1979). Although initially considered as a promising drug, undesirable side 
effects were soon linked with the use of chloramphenicol. Among those adverse 
effects, aplastic anemia and bone marrow suppression are most problematic 
(Alavi, 1983; Kucers, 1980). Increased risk of leukemia and association with the 
so-called Gray-baby syndrome has also been observed (Mulhall et al., 1983). 
Although the use of chloramphenicol in human medicine has been decreased in 
developed world, it is still used as a topical ointment. In addition, chloram-
phenicol is favored for the treatment of staphylococcal brain abscesses and 
meningitis for which less toxic remedies are not available. Chloramphenicol 
application in animals has been banned in many countries as its residues in 
carcasses of food animals could potentially cause adverse side effects to meat 
consumers (Schwarz et al., 2004). 
 
 
Figure 5. Chemical structures of chloramphenicol antibiotics. 
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The detailed pathway by which S. venezuelae produces chloramphenicol from 
chorismic acid is not yet completely clear. Since 1950, chloramphenicol is being 
produced synthetically as the procedure is relatively simple and inexpensive 
(Schwarz et al., 2004). The molecule of chloramphenicol consists of a 1,3-pro-
panediol bearing a para-nitrophenyl ring at C1 position and a dichloroacetamido 
tail at C2 position. By modifying this molecule, several derivatives of chlor-
amphenicol have been generated. Thiamphenicol has a sulfomethyl group 
attached to phenyl ring instead of nitro group. As the connection between 
thiamphenicol and aplastic anemia has never been reported, this drug is used for 
human treatment in several countries (Lambert, 2012). Florfenicol is similar to 
thiamphenicol, but contains fluorine attached to C3 of propanediol moiety 
instead of hydroxyl group. Florfenicol is used only in veterinary medicine. 
The binding site of chloramphenicol is located within the A site of PTC on 
50S ribosomal subunit. In this position, the drug overlaps with the amino acid-
containing end of an aa-tRNA. By occupying the A-site of 50S subunit, chlor-
amphenicol acts as an obstacle for the incoming aa-tRNA. Biochemical experi-
ments show that chloramphenicol obstructs small tRNA fragments from binding 
to the A-site of the PTC (Celma et al., 1971). The drug interferes with the puro-
mycin model reaction in which ribosomes containing peptidyl-tRNA in the P-site 
are exposed to puromycin (Cannon, 1968). 
Structure of chloramphenicol in complex with D. radiodurans 50S subunit 
reveals that the drug interacts with seven conserved nucleotides, which constitute 
the central loop of domain V of 23S rRNA (G2061, A2451, C2452, U2500, 
U2504, G2505 and U2506) (Schlunzen et al., 2001). 
High-resolution X-ray structures of chloramphenicol in complex with 70S 
ribosomes from E. coli and T. thermophiles are available. These structures show 
drug in different positions, rotated by 180° (Bulkley et al., 2010; Dunkle et al., 
2010). Chloramphenicol contacts the ribosome through a stacking interaction 
between its para-nitrobenzyl ring and the base C2452. A single potassium ion 
identified in PTC also contributes in binding as it links methylene hydroxyl 
group of chloramphenicol with nucleotides G2447, G2501 and G2061 of 23S 
rRNA (Bulkley et al., 2010). 
Archaea are less susceptible to chloramphenicol possibly due to rRNA 
sequence differences within the PTC. However, structure of chloramphenicol 
bound to the large ribosomal subunit of H. marismortui revealed a novel chlor-
amphenicol binding site. This second binding site is located at the entrance to 
the peptide exit tunnel and it overlaps the binding site of macrolides (Hansen et 
al., 2003). The presence of secondary binding site was confirmed with experi-
ments in which chloramphenicol was cross-linked to E. coli and H. halobium 
ribosomes (Long and Porse, 2003). The low affinity of the drug to the second 
binding site suggests that this additional site is not crucial for the translation 
inhibition. Nevertheless, the release of peptidyl-tRNA’s containing short peptides 
in vitro has been observed in the presence of chloramphenicol (Rheinberger and 
Nierhaus, 1990). 
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Several studies have demonstrated that chloramphenicol can not be viewed 
as a universal inhibitor of peptide bond formation. Instead, the inhibitory effect 
of chloramphenicol depends on the nature of mRNA being translated. For 
instance, translation of mRNAs encoding small or charged amino acids, such as 
poly(A) for lysine and poly(C) for proline is more effectively inhibited by chlor-
amphenicol than translation of mRNAs encoding larger aromatic amino acids, 
such as poly(U) for phenylalanine (Pestka, 1977). Recent experiments have 
shown that chloramphenicol blocks translation at specific locations within the 
mRNA in a context-specific manner. The two C-terminal nascent peptide 
residues as well as of the A-site acceptor strongly influence the ability of chlor-
amphenicol to inhibit peptidyl transfer. Inhibition is most efficient when the 
nascent peptide in the ribosome carries an alanine residue in its penultimate 
position (Marks et al., 2016). 
Most of the resistance to chloramphenicol and its derivatives is mediated by 
chloramphenicol acetyltransferases (CATs). All CATs transfer an acetyl group 
from a donor molecule to the hydroxyl group at C3 of the phenicol molecule 
(Murray and Shaw, 1997). However, CATs do not confer resistance to flor-
fenicol, because their hydroxyl group at C3 is replaced by fluorine (Schwarz et 
al., 2004). Efflux systems encoded by elm genes constitute the second important 
resistance mechanism. Other mechanisms including methylation of A2503 by 
the methyltransferase Cfr, mutations in 23S rRNA and porin alternations have 
been described (Kehrenberg et al., 2005). 
 
 
1.1.5. Oxazolidinones 
There are three major antibiotic classes of purely synthetic origin: (1) the quino-
lones that target bacterial topoisomerases, (2) sulfonamides that interfere with 
folate biosynthesis, and, (3) the oxazolidinones that are translation inhibitors. In 
1970s, an American chemical company DuPont started a screening program in 
order to identify novel agents for treatment of certain plant diseases. This 
screening leaded to discovery of first bioactive oxazolidinones (Fugitt and 
Luckenbaugh, 1978). A common characteristic of these compounds is the 
presence of a 2-oxazolidinone ring, which is a heterocyclic 5-membered ring 
bearing both a nitrogen and an oxygen atom. Compounds Dup 105 and Dup 721 
gained special attention because they exhibited promising characteristics 
required for developing new medications. These features included an ability to 
inhibit bacterial translation via novel mechanism, activity against multidrug-
resistant Gram-positive pathogens and inability to generate resistant mutants in 
vitro (Slee et al., 1987). However, the safety profile of Dup 105 and Dup 721 
was deemed to be inappropriate for human use (Ranger, 2004). 
Extensive synthesis and examination of oxazolidinone analogues continued 
at The Upjohn Company. Finally, two compounds were found to exhibit good 
balance between antibacterial efficacy, pharmacokinetics, water solubility and 
other properties. These compounds were a piperazine analog eperezolid (PNU-
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100592) and a morpholine analog linezolid (PNU-100766). Both drug candi-
dates demonstrated acceptable safety, bioavailability and clearance in animal 
tests (Slatter et al., 2002). Eperezolid and linezolid entered into human clinical 
trials in 1994 and 1995, respectively. Eventually, linezolid (Figure 6) was pre-
ferred for further studies due to more favorable pharmacokinetic profile (Zurenko 
et al., 1997). Linezolid successfully passed through Phase II and Phase III trials 
and was approved for human use in 2000. The drug is currently marketed by 
Pfizer under the name Zyvox®. 
 
 
Figure 6. The structure of an oxazolidinone antibiotic linezolid. 
 
The molecule of linezolid is composed of three aromatic rings (oxazolidinone 
A-ring, fluorophenyl B-ring, morpholine C-ring) and an acetamide C5-tail (Figure 
6). Early experiments showed that eperezolid competes with chloramphenicol 
and puromycin for ribosome binding (Lin et al., 1997). Subsequent crosslinking 
experiments demonstrated that oxazolidinones interact with components of the 
PTC (Colca et al., 2003). 
Ipplito and others have published a structure of linezolid bound to H. maris-
mortui 50S subunit with and without the addition of CCA-N-acetylphenylalanine 
(CCA-Phe), an analog of the 3'-terminus of aminoacyl-tRNA (Ippolito et al., 
2008). In these structures, linezolid is seen in the A site of the PTC. The structure 
reveals that linezolid and CCA-Phe bind the PTC simultaneously, indicating 
that the drug does not interfere with the binding of peptidyl-tRNA substrates to 
the P-site (Ippolito et al., 2008). 
Another crystal structure shortly became available in which linezolid is 
bound to 50S ribosomal subunit from D. radiodurans. The binding region of 
linezolid was shown to overlap those of chloramphenicol and the aminoacyl 
moiety of an A-site bound tRNA. Morpholine ring of the molecule heads 
toward the intersubunit interface, whereas oxazolidinone ring is oriented in the 
general direction of the ribosomal tunnel (Wilson et al., 2008). 
According to the proposed model for the mechanism of action, linezolid 
interferes with both translation initiation and elongation phases. When bound to 
the A-site of the 50S subunit, linezolid perturbs the orientation of nucleotide 
U2585 of 23S rRNA (Wilson et al., 2008). As the correct conformation of U2585 
is required for the positioning of initiator-tRNA to the P-site (Schmeing et al., 
2005), the drug is thought to inhibit translation initiation (Aoki et al., 2002). 
When bound to the A-site of a translating ribosome, linezolid does not interfere 
neither with the binding of aa-tRNA:EF-Tu:GTP ternary complex to the initial 

O
O
NH
O
CH
N
F
NO
25 
A/T site of the ribosome nor the GTP hydrolysis by EF-Tu (Matassova et al., 
1999). However, linezolid blocks the subsequent accommodation of an in-
coming tRNA into the A-site, similarly to tetracycline. As a result, aa-tRNA 
dissociates from the ribosome and peptidyl-tRNA becomes “locked” in the P-site 
(Wilson et al., 2008). Similarly to chloramphenicol, linezolid does not actively 
block formation of every peptide bond, but rather stalls ribosomes at specific 
mRNA locations. The action of linezolid is defined by the nature of the penul-
timate residue of the nascent peptide as well as by the amino acid residues 
directly participating in peptide bond formation. The presence of Ala in the 
penultimate position of the peptide stimulates the action of linezolid, while Gly 
strongly counteracts the inhibitory effect (Marks et al., 2016). However, the 
mechanistic principles of context specificity are not completely understood. 
Linezolid is a bacteriostatic agent active against Gram-positive bacteria. It is 
used mainly for treatment of bacteremia, pneumonia and skin diseases, including 
infections caused by vancomycin-resistant Enterococcus and methicillin-resistant 
Staphylococcus. Oxazolidinones have been shown to cross-link to the PTC of 
human mitochondrial ribosomes (Leach et al., 2007). This can be the expla-
nation for some adverse effects like diarrhea, nausea and headache, although 
linezolid is generally well tolerated by patients. 
Numerous attempts have been made in order to discover new oxazolidinone 
analogues and to improve the potency of existing molecules. Although linezolid 
is so far the only commercial oxazolidinone, several novel oxazolidinones are 
currently under investigation. Radezolid is the first biaryloxazolidinone that has 
recently successfully completed Phase II clinical trials. Radezolid displays 
improved antibacterial properties in comparison with linezolid, as it also inhibits 
growth of Gram-negative bacteria and retains activity against linezolid-resistant 
strains (Locke et al., 2010). The molecules of second-generation oxazolidinones 
are generally larger as they contain an extra D-ring or side chain. Improved 
molecules are able to form additional interactions with the ribosome, thus 
explaining the greater potency of radezolid (Shaw et al., 2008). Another oxa-
zolidinone analogue, tedizolid, has entered into Phase III trials. Tedizolid is 
suggested to be less toxic when compared to linezolid, as it does not bind to 
mitochondrial ribosomes (Das et al., 2012). 
Resistance to linezolid is not widespread, but can occur through mutations in 
the 23S rRNA region associated with the binding site of the drug (nucleotides 
A2451, C2452, U2504 and G2505; reviewed in Shaw and Barbachyn, 2011 and 
in Wilson, 2009). Resistance can also be conferred by mutations in 23S rRNA 
nucleotides that do not interact with the drug. One such mutation, G2576U, acts 
via perturbing the position of G2505 and U2506 (Wilson et al., 2008). Further-
more, reduced susceptibility to oxazolidinones is associated with mutations in 
genes encoding ribosomal proteins L3, L4 and L22 (Locke et al., 2009; Wong et 
al., 2010). Cfr methytransferase that modifies 23S rRNA nucleotide A2503 
within the PTC is responsible for the cross-resistance to oxazolidinones, macro-
lides, phenicols, pleuromutilins, lincosamides and streptogramin A (Long et al., 
2006). 
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1.1.6. Thiopeptides 
Thiopeptide class of antibiotics is distinctive by their highly modified, sulfur-
containing macrocyclic structure and high molecular weight. Thiopeptide mole-
cules compose largely of heteroaromatic rings such as indoles, thiazoles, 
oxazoles and pyridines that are linked together (Figure 7). This class comprises 
more than 100 compounds that can be subdivided into subfamilies according to 
the size of the macrocyclic ring(s) or the oxidation state and substitution pattern 
of the central pyridine core (Bagley et al., 2005; Malcolmson et al., 2013). 
Thiopeptides possess either 26-, 29- or 35-membered macrocyclic rings. The 
most-studied thiopeptides belong to classes containing 26-membered macro-
cyclic ring (thiostrepton, micrococcin, siomycin, thiocillin, nosiheptide) and 29-
membered ring (GE2270A) (Figure 7). 
The first discovered thiopeptide was isolated from Micrococcus ssp in 1948 
and was named micrococcin (Su, 1948). Thiostrepton was first isolated in 1954 
from an actinomycete Streptomyces azureus (Donovik et al., 1955) but its 
structure was not completely solved until 1983 (Hensens and Albers-Schonberg, 
1983). It took 60 years before the details of thiopeptide biosynthesis became 
evident. Maturation of a thiopeptide molecule begins with the synthesis of a 50–
60 amino acids long precursor protein by the ribosome. The precursor must pass 
through a cascade of post-translational modifications before the active com-
pound is formed (Walsh et al., 2010; Kelly et al., 2009; McIntosh et al., 2009). 
 
 
Figure 7. Structures of thiopeptide antibiotics thiostrepton and GE2270A. 
 
Thiostrepton has been shown to be effective especially against Gram-positive 
bacteria as well as against malaria-causing protozoan parasite Plasmodium 
falciparum (McConkey et al., 1997). Gram-negative organisms are naturally 
resistant to thiostrepton, as the drug is unable to penetrate their outer membrane. 
Although thiopeptides have been applied in veterinary medicine, their use in 
treatment of human infections has faced several problems due to chemical and 
physical properties of the molecules. The toxicity of thiopeptides to eukaryotes 
is relatively low. On the other hand, low solubility in water complicates their 
parenteral administration and the large size of molecules creates problems in 
oral bioavailability. One opportunity for overcoming these drawbacks could be 
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the reduction of the size of large thiopeptide molecules without affecting their 
antibacterial activity (Nicolaou et al., 2005). 
Thiopeptides exhibit different mechanisms of action depending on macro-
cycle size. The target of compounds with 35-membered rings remains uncertain, 
although they maintain antibacterial activity (Just-Baringo et al., 2014). Thio-
peptides with 26-membered macrocycles bind to 50S ribosomal subunit while 
those with a 29-membered ring, such as GE2270A, bind to EF-Tu. GE2270A 
has been shown to inhibit the formation of EF-Tu:GTP:aa-tRNA ternary complex 
(Anborgh and Parmeggiani, 1991). So far, GE2270A remains the only thio-
peptide that has been completed Phase I clinical trials for human treatment 
(Butler, 2008). 
Studies of crystal structures of D. radiodurans 50S ribosomal subunit in 
complex with thiostrepton, nosiheptide and micrococcin have elucidated the 
binding site of thiopeptides on the ribosome. Thiostrepton was shown to bind 
into crevice between helices 43 and 44 of 23S rRNA and N-terminal domain of 
ribosomal protein L11 (Harms et al., 2008). Thiostrepton forms hydrogen bonds 
with nucleotides A1067 and A1095 that are situated at the tips of H43 and H44, 
respectively. Thiostrepton does not bind to free L11, although the absence of 
L11 decreases dramatically the binding affinity of the antibiotic (Porse et al., 
1998). 
The target site of thiostrepton as well as related compounds nosiheptide, sio-
mycin and micrococcin is recognized as a GTPase-associated center since it 
operates as the binding site for translational GTPases (Margus et al., 2007; 
Lentzen et al., 2003). Thiostrepton mimics EF-G region V, interferes with the 
stable interaction between EF-G and the ribosome and prevents ribosome-
dependent GTP hydrolysis by EF-G (Cameron et al., 2002; Harms et al., 2008). 
An EF-G mutant lacking domains IV and V is insensitive to thiostrepton 
(Walter et al., 2011). In addition, thiostrepton has been shown to inhibit stable 
ribosome binding of ribosome protection proteins Tet(O) and Tet(M) (Connell 
et al., 2003a; Mikolajka et al., 2011), elongation factor 4 (LepA) (Walter et al., 
2011), BipA (Mikolajka et al., 2011) and IF2 (Grunberg-Manago et al., 1972).  
Despite of their similar structure, thiostrepton and micrococcin are shown to 
have different effect on the GTPase activity of EF-G. Similarly to thiostrepton, 
micrococcin inhibits the GTPase activities of translational GTPases Tet(M), 
EF4, BipA and IF2 (Mikolajka et al., 2011). However, micrococcin does not 
interfere neither with the binding of EF-G:GTP to the ribosome nor with the 
ribosome-induced GTPase activity of EF-G and, contrary to thiostrepton, 
enhances the GTPase activity of EF-G (Lentzen et al., 2003). This essential 
difference can be explained by the fact that micrococcin binds to slightly 
different position and interacts with A1095 rather than with A1067 (Harms et 
al., 2008). By binding to the ribosome, micrococcin can stabilize the interaction 
between proteins L11 and L7, thereby bending L7 into position in which it can 
interact with EF-G and stimulate the GTP turnover (Mikolajka et al., 2011). 
Cross-resistance between thiopeptides and other antibiotics is unlikely to 
happen because the binding site of thiopeptides is unique (Figure 1). Thiostrepton 
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producer S. azureus protects his own ribosomes by methylation of A1067 
(Thompson et al., 1982). Although resistance development to thiopeptides has 
not been documented in vivo, several resistance-conferring spontaneous mutations 
have been found during selection experiments. Resistance to thiostrepton can be 
conferred by methylation or base changes at 23S rRNA conserved positions 
A1067 and A1095 (Cundliffe and Thompson, 1979; Hummel and Bock, 1987b; 
Rosendahl and Douthwaite, 1993). Additionally, mutations in gene encoding 
protein L11 can also be responsible for the resistance (Cameron et al., 2004). 
 
 
1.1.7. Lincosamides 
The prototypical member of lincosamide group is lincomycin. It was discovered 
as a fermentation product of actinomycete Streptomyces lincolnensis (Mason et 
al., 1962). Later studies revealed that lincomycin can also be produced by other 
organisms, such as Streptomyces espinosus and Actinomyces roseolus (Wilson 
et al., 2009).  
The molecule of lincomycin (Figure 8) comprises a propyl-pyrrolidinyl moiety 
(a proline derivative) and a lincosamine sugar ring that are connected via an 
amide bond. Although licensed for use in human medicine, lincomycin is rarely 
used nowadays. A large number of lincomycin modifications have been prepared 
(Magerlein, 1971) but only a few of them are used in medicine. Clindamycin is 
a semi-synthetic derivative of lincomycin in which the 7-hydroxyl group is 
replaced by chlorine (Figure 8) (Lewis, 1974). Consequently, clindamycin is 20 
times more effective than lincomycin in inhibiting the growth of E. coli (Douth-
waite, 1992). Clindamycin is most widely used in medicine due to highest 
potency and good oral absorption. Another clinically important derivative of 
lincomycin is pirlimycin, which contains six-membered cyclic amino acid amide 
instead of the five-membered proline ring (Birkenmeyer et al., 1984). Pirlimycin 
is used to treat bovine mastitis (Watts and Yancey, 1994). 
 
 
Figure 8. Structures of lincosamide antibiotics lincomycin and clindamycin. 
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Lincosamides have only a limited spectrum of activity, as Gram-negative bacteria 
tend to be intrinsically resistant to lincosamides. Nevertheless, lincosamides are 
active against Gram-positive bacteria, such as the genera Staphylococcus and 
Streptococcus (Spizek and Rezanka, 2004). Moreover, clindamycin has been 
shown to be active against some protozoa and can serve as an antimalarial drug 
(Lell and Kremsner, 2002).  
Lincosamides interact with the A- and the P-site of the 50S ribosomal subunit 
and directly inhibit peptide bond formation. They cause dissociation of short 
peptidyl-tRNAs from the ribosome in early elongation phase but lose their 
effect when peptides have grown beyond a critical length (Tenson et al., 2003). 
Currently, there are three crystallographically resolved structures of clin-
damycin bound to the 70S ribosome or to 50S ribosomal subunit. The propyl-
pyrrolidinyl group of clindamycin occupies the same region as the aminoacyl-
moiety of A-site bound tRNA and interferes with binding of aminoacyl-tRNA 
into the A-site (Tu et al., 2005; Dunkle et al., 2010). In this region, the binding 
site of clindamycin partially overlaps with that of chloramphenicol (Schlunzen 
et al., 2001). The sugar moiety of clindamycin extends into the peptide exit tunnel 
and overlaps with the desosamine sugar of macrolides (Tu et al., 2005). 
Consistently, lincosamides have been shown to compete with both chloram-
phenicol and erythromycin for ribosome binding (Fernandez-Munoz et al., 
1971). According to the crystal structures, several hydrogen bonds can form 
between the hydroxyl groups of sugar ring of clindamycin and nucleotides 
within the PTC and the peptide exit tunnel, such as A2058, A2059, G2505, and 
A2503 (Schlunzen et al., 2001, Tu et al., 2005, Dunkle et al., 2010). This is 
consistent with earlier experiments in which the interactions between clin-
damycin and lincomycin with E. coli ribosomes were studied by chemical foot-
printing. Both drugs protected 23S rRNA bases A2058, A2451, G2505 and 
G2061. Clindamycin additionally protected A2059. Nevertheless, the affinity of 
the two drugs for the ribosome is approximately the same (Douthwaite, 1992). 
The propyl tail of lincosamides is suggested to be highly flexible and therefore 
less relevant in the binding to the ribosome (Wilson, 2009). 
As macrolides, lincosamides and streptogramin B bind to an overlapping 
region, they are together often referred as MLSB group of antibiotics despite of 
large differences in their molecular structure. Addition of one or two methyl 
groups to 23S rRNA nucleotide A2058 renders cells resistant to MLSB group of 
drugs and is the most prevalent cause of resistance to lincosamides (Poehlsgaard 
and Douthwaite, 2003). Methylation of A2058 is carried out by rRNA methyl-
transferases encoded by erm genes (Roberts, 2011). Another methyltransferase, 
Cfr, confers resistance to five different classes of antibiotics (phenicols, lin-
cosamides, oxazolidinones, pleuromutilins, and streptogramins A) by adding a 
methyl group to nucleotide A2503 of 23S rRNA (Long et al., 2006).  
Active efflux across the cell membrane is a less common lincosamide 
resistance mechanism. It can be mediated by car, lsa, lmr and vga gene products 
(Roberts, 2011). An unusual co-resistance phenotype has been described in a 
Streptococcus agalactiae strain that exhibits resistance to lincosamides, strepto-
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gramins A and pleuromutilins (co-called LSAP phenotype). Studies have revealed 
that such type of resistance is caused by the presence of a lsa(C) gene encoding 
for a specific ABC transporter (Malbruny et al., 2011). Other lincosamide re-
sistance mechanisms include mutations in 23S rRNA nucleotides A2058 and 
A2059 (Poehlsgaard et al., 2005) and enzymatic inactivation of drugs via 
adenylation of their 4- or 3-hydroxyl group (Brisson-Noel et al., 1988). 
 
 
1.1.8. Streptogramins 
Family of streptogramins is unique among antibiotics as it consists of a mixture 
of two chemically unrelated substances, types A and B (Figure 9). Both strepto-
gramin A and B (SA and SB) substances are co-synthesized by the same 
producer organism in a 7:3 ratio (Mast and Wohlleben, 2014). SA substances are 
cyclic polyunsaturated macrolactones that are synthesized by polyketide 
synthases and nonribosomal peptide synthetases. SB compounds are cyclic hexa-
depsipeptides of nonribosomal origin (Barriere et al., 1998). 
The family obtained its name from the mixture of compounds that was 
isolated from Streptomyces graminofaciens (Charney et al., 1953). During few 
years, several other streptogramins were discovered from strains of Strepto-
myces, Micromonospora, Actinoplanes and Actinomadura. However, these new 
antibiotics such as mikamycin, synergistin and madumycin did not become 
subjects for further development (Ahmed and Donaldson, 2007; Barrière et al., 
1998). 
 
Figure 9. Structures of pristinamycin components pristinamycin I (SB) and pristin-
amycin II (SA).  
 
Pristinamycin was found from Streptomyces pristinaespiralis and consists of a 
mixture of streptogramine A (SA) type pristinamycin II and streptogramin B 
(SB) type pristinamycin I (Figure 9). Pristinamycin is an effective drug against 
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Gram-positive bacteria, including methicillin-resistant S. aureus as well as van-
comycin-resistant S. aureus and Enterococcus faecium. Streptogramins are 
generally unable to penetrate the outer membrane of most Gram-negative 
bacteria. Nevertheless, pristinamycin is active against a few Gram-negative 
pathogens, Mycoplasma and Legionella (Mast and Wohlleben, 2014). The use 
of pristinamycin in therapy is limited due to poor solubility in water. Never-
theless, the drug is available for oral use in some countries (Eliopoulos et al., 
2005). To overcome the solubility of natural streptogramins, an injectable semi-
synthetic derivative Synercid was developed. Synercid is composed of a 
mixture of the SA type dalfopristin and the SB type quinupristin (Barrière et al., 
1994). However, the antibacterial efficiency of Synercid is low and the use of 
the drug is associated with some severe side effects (Delgado et al., 2000). A 
novel pristinamycin-derivative NXL-103 is currently in Phase II clinical trial. 
NXL-103 is a mixture of SA type flopristin and the SB type linopristin. This 
streptogramin drug candidate is reported to have a 2-fold higher activity than 
pristinamycin and shows fewer side effects than Synercid (Politano and Sawyer, 
2010). It has been suggested that NXL-103 is more effective mainly due to 
flopristin, as its counterpart dalfopristin exhibits significantly lower anti-
microbial activity (Dupuis and Leclercq, 2006). 
Another commercially used streptogramin was isolated from Streptomyces 
virginiae, and was named virginiamycin. It is composed of a mixture of 
virginiamycin M (type SA) and virginiamycin S (type SB) and has been used as 
an animal feed supplement for disease prevention and growth promotion (Yates 
and Schaible, 1962). Since 1999, the use of virginiamycin as a growth promoter 
is banned in the European Union, but it is still used in some countries including 
USA, China and Japan (Casewell et al., 2003). 
To a date, crystal structures of 50S ribosomal subunits or 70S ribosomes from 
H. marismortui (Hansen et al., 2003; Tu et al., 2005), D. radiodurans (Harms et 
al., 2004) and E. coli (Noeske et al., 2014) in complex with streptogramins are 
available. Both SA and SB type substances bind to the 50S ribosomal subunit. SA 
binds into a hydrophobic pocket within the PTC and forms hydrophobic inter-
actions as well as hydrogen bonds with the surrounding nucleotides. The 
binding site of SA molecule overlaps with the aminoacyl moieties of both A- 
and P-tRNAs and therefore prevents tRNAs from positioning into both A- and 
P-sites (Tu et al., 2005; Hansen et al., 2003; Harms et al., 2004). Consequently, 
peptide bond formation is hampered and elongation of the growing polypeptide 
chain stops. Binding of SA to the ribosome is suppressed when the P-site or the 
A-site is occupied. Therefore, SA molecules do not inhibit ribosomes that are 
actively engaged in protein synthesis (Chinali et al., 1988; Cocito et al., 1997). 
Surprisingly, the bacteriostatic activity of SA has been shown to persist for a 
prolonged period even after removal of the compound (Parfait and Cocito, 
1980; Nyssen et al., 1989). As studies of the D. radiodurans 50S ribosomal 
subunit in complex with Synercid have shown, binding of dalfopristin induces a 
conformational change of 23S rRNA nucleotide U2585. U2585 is known to be 
involved in correct positioning of tRNA substrates and peptide bond formation 
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(Schmeing et al., 2005). In a dalfopristin-induced alternative conformation, 
U2585 forms hydrogen bonds with G2588 and C2606. Spontaneous reversal of 
such non-productive U2585 conformation occurs relatively slowly after removal 
of the drug, thus explaining the post-antibiotic effect (Harms et al., 2004). 
The presence of SA substance in its target site has been shown to enhance the 
binding of SB substance to the ribosome (Contreras and Vazquez, 1977b). 
Binding of SA type dalfopristin alters the conformation of 23S RNA nucleotide 
A2062 within the PTC. The base of A2062 moves toward the dalfopristin 
molecule, thus enabling better accommodation for SB compound. A2062 forms 
interactions with both streptogramin A and B (Harms et al., 2004; Noeske et al., 
2014). 
The binding site of SB substances is localized within the ribosomal exit tunnel, 
adjacent to SA compound. Quinupristin has been shown to form hydrophobic 
interactions with nucleotides of domain II, IV and V of 23S rRNA and hydrogen 
bonds with A2062 and C2586 (Harms et al., 2004). The presence of SB 
compounds in the exit tunnel blocks the elongation process after a few cycles of 
peptide bond formation. As a result, the short peptidyl-tRNA is released from the 
ribosome (Chinali et al., 1988). Therefore, the mode of action of SB substances is 
similar to that of the macrolide antibiotics. Unlike SA compounds, SB molecules 
also interact with ribosomes engaged in protein synthesis (Vasquez, 1975). 
SA and SB type antibiotics show moderate bacteriostatic activity when 
applied individually. However, the combination of both SA and SB substances is 
bactericidal as it results in a strong synergistic effect that is up to 100-fold higher 
than measured for both substances separately (Vazquez, 1966; Di Giambattista 
et al., 1989). 
Resistance to SA and SB compounds can be different due to differences in their 
chemical structures and binding sites. Synergy between SA and SB compounds 
may reduce the likelihood of acquired resistance mutations at their binding sites. 
SB substances are often classified into MLSB group together with macrolides 
and lincosamides due to their overlapping binding sites around the peptide exit 
tunnel and their cross-resistance due to target modification (Canu and Leclercq, 
2001; Tenson et al., 2003). SA compounds can in turn show cross-resistance with 
lincosamides and pleuromutilins and are therefore grouped to the LSAP group 
(Mast and Wohlleben, 2014). MLSB resistance phenotype does not confer 
resistance to SA, whereas SA resistance is often associated with SB resistance 
(Barriere et al., 1998; Cocito et al., 1997). 
Resistance to MLSB antibiotics can be conferred by rRNA methylases, which 
add one or two methyl groups to A2058 in 23S rRNA thus blocking antibiotics 
from attaching to the ribosome (Roberts, 2011). Both SA and SB compounds can 
be removed from the cell via active efflux. Resistance to streptogramins may 
also be caused by enzymatic inactivation of the drugs. SA compounds are 
inactivated by acetyl transferases that are encoded by the vat and satA genes. SB 
substances can be degraded by hydrolases that are products of the vgb genes 
(Allignet and el Solh, 1995). Mutations of A2062 can give rise to both SA and 
SB resistance (Depardieu and Courvalin, 2001). 
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1.1.9. Other protein synthesis inhibitors 
Translation is a complex and highly regulated process that can be divided into 
distinct phases. Research has been identified natural, semi-synthetic or fully 
synthetic antibiotics that inhibit every translation phase. In addition to large 
classes, many smaller groups of antibiotics are known. There are also numerous 
antibiotics that cannot be grouped together with other compounds due to their 
unique structure or mechanism of action. Some of these compounds (e. g. 
antimicrobial peptides) are considered as potential candidates for the develop-
ment of new therapeutic antimicrobial agents, while some are used in molecular 
biology as research tools (e. g. puromycin) or have gained interest due to their 
additional effects (e. g. anisomycin). There are many excellent publications on 
the subject (Hermann, 2005; McCoy et al., 2011; Poehlsgaard and Douthwaite, 
2005; Wilson, 2009; Wilson, 2014). The following is a short review of some 
translation inhibitors belonging to smaller antibiotic groups. 
 
Kirromycin 
Kirromycin (Figure 10) is produced by Streptomyces collinus. It was the first 
discovered antibiotic that targets EF-Tu (Wolf et al., 1972). Other discovered 
members of kirromycin family include aurodox (N-methyl kirromycin) from 
Streptomyces goldingiensis (Berger et al., 1973) and mocimycin from 
Streptomyces ramocissimus (Vos, 1972). However, the latter turned out to be 
identical with kirromycin (Vos and Verwiel, 1973). Kirromycin is a narrow-
spectrum antibiotic. It exhibits activity against Streptococci, some Enterococci, 
Neisseria gonorrhoeae, Haemophilus influenza, and the malaria parasite Plas-
modium falciparum with no toxic effects on higher eukaryotic cells (Schmid et 
al., 1978). Natural resistance to the drug is more spread among Gram-positive 
bacteria as they harbor EF-Tu with less conserved kirromycin-binding site 
(Landini et al., 1993). The kirromycin producer S. ramocissimus has three EF-
Tu isoforms. Two of those are sensitive to the drug whereas one is resistant and 
provides a self-resistance mechanism (Olsthoorn-Tieleman et al., 2007). The 
molecule of kirromycin is a linear polyketide containing three intramolecular 
ring systems: the pyridone ring, the central tetrahydrofurane moiety and a 
goldinonic moiety (Fabbretti et al., 2013). The antibiotic is synthesized by a 
complex of type I polyketide synthase and nonribosomal peptide synthetases 
(Weber et al., 2008). A number of natural and semi-synthetic kirromycin ana-
logs have been described that all share similar mechanism of action. Kirromycin 
binds at the interface of domains 1 and 3 of EF-Tu in the EF-Tu:GDP complex. 
Mutations on each side of the interface can render EF-Tu insensitive to 
kirromycin (Abdulkarim et al., 1994).  
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Figure 10. The structure of kirromycin.  
 
EF-Tu:GTP:kirromycin ternary complex is still able to bind aminoacyl-tRNA 
and enter the ribosomal A-site. However, after GTP hydrolysis, EF-Tu does not 
dissociate from the ribosome. The aminoacyl end of the tRNA remains in 
contact with EF-Tu and is unable to enter the PTC, whereas the anticodon of the 
tRNA is in the decoding center of the 30S subunit (Stark et al., 1997). Kirro-
mycin induces a conformation of EF-Tu:GDP that is similar to the GTP form, 
thus preventing its release from the ribosome after and despite hydrolysis of 
GTP to GDP and Pi (Vogeley et al., 2001). Consequently, the ribosome stalls 
and also blocks all other ribosomes upstream on the same mRNA. Kirromycin-
like antibiotics have been effectively used for studying the structure-function 
relationships of EF-Tu. 
 
Anisomycin 
Anisomycin (Figure 11) was purified from the fermentation broth of Strepto-
myces griseolus (Sobin and Tanner, 1954). Anisomycin does not inhibit 
bacterial translation. Instead, this drug binds into the A-site of the PTC of 
archeal and eukaryotic ribosomes (Grollman, 1967; Barbacid and Vazquez, 
1974). The molecule of anisomycin is composed of a methoxyphenyl group and 
a pyrrolidine ring (Beereboom et al., 1965). In the Haloarcula marismortui 
large ribosomal subunit, the methoxyphenyl group of anisomycin inserts into 
the crevice that normally accepts the amino acid side-chains of A-site bound 
aminoacyl-tRNA. The methoxyphenyl moiety stacks onto the 23S rRNA 
nucleotide C2452, pyrrolidine group forms a hydrogen bond with A2451 and 
the hydroxyl group of anisomycin interacts with U2504 (Hansen et al., 2003, 
Rodriguez-Fonseca et al., 1995). The binding site overlaps with those of 
chloramphenicol, puromycin and linezolid. In bacterial large ribosomal subunit, 
U2504 forms a base pair with C2452 thus obstructing the binding site of 
anisomycin (Wilson, 2009). 
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Figure 11. The structure of anisomycin. 
 
It has been reported that anisomycin also inhibits binding of the P-site sub-
strates (Carrasco and Vazquez, 1972). However, latter structural analysis 
showed that the P-site substrate is out of the reach of anisomycin (Hansen et al., 
2003). It is still possible that anisomycin can inhibit P-site binding indirectly by 
inducing changes in the PTC structure. Resistance to anisomycin can be 
conferred by mutation of the nucleotide C2452, which is in direct contact with 
the drug and nucleotides G2447, G2576, C2499 and U2500 that are located 
close to the A-site crevice and cause subtle changes within the PTC (Hummel 
and Bock, 1987a; Blaha et al., 2008). Interestingly, anisomycin has many 
activities apart from being a translation inhibitor. It can act as a modulator of 
eukaryotic signal transduction (Torocsik and Szeberenyi, 2000), exhibits 
antitumor activity (You et al., 2013) and is considered as a potential psychiatric 
drug (Barrientos et al., 2002).  
 
Puromycin 
Puromycin was originally isolated from Streptomyces alboniger (Porter et al., 
1952). This antibiotic inhibits translation on ribosomes of all three kingdoms of 
life and therefore cannot be used in therapy. The molecule of puromycin is a 
structural analogue of the 3’ end of an aminoacyl-tRNA (Waller et al., 1953) 
(Figure 12). It consists of an aminonucleoside that is linked to a phenylalanine 
moiety via an amide bond (but not via an ester bond as aminoacyl-tRNA). 
Puromycin binds into the A-site region of the PTC via its 3’ terminal adenine. 
When located in the A-site, the nascent polypeptide is covalently linked from 
the peptidyl-tRNA to the amino acid moiety of puromycin. When puromycin 
has acquired the nascent polypeptide, the drug dissociates from the ribosome 
due to low affinity. Peptidyl-puromycin can be transferred into the P-site but no 
further peptidyl transfer takes place as the ribosome is unable to cleave the 
amide bond (Wilson, 2009). This leads to a premature termination of translation 
process (Nathans, 1967). Since decades, puromycin has been an extremely 
important tool for studying of peptidyltransferase reaction mechanisms. 
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Figure 12. The structures of puromycin and 3’ end of an aminoacyl-tRNA. 
 
Sparsomycin 
Sparsomycin is a universal translational inhibitor as it affects peptidyltrans-
ferase activity in bacteria, archea and eukaryotes. Therefore, this compound is 
not suitable for usage neither for human nor veterinary therapy, although it has 
been shown to possess antitumor activity against human epidermoid carcinoma 
cells (Owen et al., 1962). Sparsomycin is a fermentation product of Streptomyces 
sparsogenes (Argoudelis and Herr, 1962). The molecule of the compound is 
composed of a uracil acrylic moiety and a mono-oxodithioacetal moiety (Wiley 
and MacKellar, 1976). Crystal structure of Deinococcus radiodurans 50S 
ribosomal subunit in complex with sparsomycin showed that the uracil ring of 
sparsomycin forms stacking interactions with the highly conserved P-site base 
A2062 of 23S rRNA (Bashan et al., 2003). This observation is consistent with 
previous cross-linking experiments (Porse et al., 1999). By binding to A2062, 
sparsomycin significantly alters the conformation of nucleotides of the PTC 
(Bashan et al., 2003). In addition to contacts with A2062, sparsomycin also 
interacts with the P-site substrate. Indeed, ribosomes do not bind sparsomycin 
with high affinity unless the P-site is occupied by an N-blocked aminoacyl-
tRNA molecule (Lazaro et al., 1991b). Thus, the first peptide bond formation is 
insensitive to the drug (Busiello and Di Girolamo, 1973). Analysis of Halo-
arcula marismortui crystal structure located sparsomycin along the backbone of 
nucleotides C75 and A76 of the P-site tRNA and the linked peptide (Hansen et 
al., 2002). By interacting with both 23S rRNA and peptidyl-tRNA, sparsomycin 
enhances the binding of peptidyl-tRNA to the P-site (Monro et al., 1969; 
Hansen et al., 2002). The tail of sparsomycin molecule occupies the position 
that is needed for normal accommodation of aminoacyl-tRNA 3’ terminus into 
the A-site. Thus, the drug impedes peptide bond synthesis by interfering with 
the binding of tRNA to the A-site (Pestka, 1969). Other A-site attacking anti-
biotics, such as chloramphenicol, lincomycin and puromycin compete with 
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sparsomycin for binding to the ribosome (Ottenheijm et al., 1986; Lazaro et al., 
1991a). It has been shown that sparsomycin promotes ribosomal translocation in 
the absence of EF-G and GTP (Fredrick and Noller, 2003). Resistance to 
sparsomycin is rare as this drug targets a very critical and conserved region of 
the ribosome. It has been suggested that insusceptibility of producer organism 
S. sparsogenes might be related to an alteration in the sparsomycin permeability 
barrier (Lazaro et al., 2002).  
 
Pactamycin 
Pactamycin was isolated from Streptomyces pactum (Bhuyan, 1962). Despite of 
numerous studies, the mode of action of pactamycin is not unambiguously 
understood. Structurally, pactamycin is a complex aminocyclopentitol antibiotic 
bearing a cyclopentane core (Wiley et al., 1970). This antibiotic gained interest 
as a potential anti-tumor agent (Bhuyan et al., 1961) but the interest ceased 
when it appeared that pactamycin inhibits both prokaryotic and eukaryotic 
ribosomes (Colombo et al., 1966). According to initial studies, the binding site 
of pactamycin was located to the P-site of the ribosome (Cohen et al., 1969). 
However, structural studies have specified that the binding site of the drug is 
actually in the E-site of 30S subunit (Carter et al., 2000; Brodersen et al., 2000). 
Pactamycin interacts with the 16S rRNA helices 23 and 24 with the universally 
conserved 16S rRNA nucleotides G693 (h23) and C795 (h24) being most 
crucial for binding (Brodersen et al., 2000; Woodcock et al., 1991). Pactamycin 
mimics an RNA dinucleotide and was thought to disrupt the path of real mRNA 
(Brodersen et al., 2000). Pactamycin was shown to block the formation of new 
polypeptide chains, while allowing the completion of chains already started on 
polyribosomes (Macdonald and Goldberg, 1970). When bound to bacterial 30S 
ribosomal subunit, pactamycin prevents dissociation of initiation factors from 
the 30S initiation complex, thus interfering with the formation of functional 70S 
ribosomes (Kappen and Goldberg, 1976). In addition, pactamycin inhibits 
initiation factor and GTP-dependent binding of tRNA to the P-site (Cohen et al., 
1969). However, latter experiments demonstrated that pactamycin cannot be 
regarded as a selective inhibitor of initiation. The drug was shown to inhibit 
both chain elongation and initiation in overlapping concentration ranges, whereas 
effect on elongation was more apparent at higher pactamycin concentrations 
(Tai et al., 1973). Surprisingly, a comprehensive study of effects of pactamycin 
on initiation and elongation revealed that the drug interferes with the first 
translocation reaction whereas no inhibitory effect on the initiation phase was 
noted (Dinos et al., 2004). Nevertheless, a study by Dinos and co-workers did 
not explicitly rule out subtle possible inhibitory effects on initiation and 
pactamycin is therefore classified as both an initiation and elongation inhibitor 
(Wilson, 2009). Resistance to pactamycin has been studied in an archaea 
Halobacterium halobium. Resistance was caused by mutations A694G, C795U 
and C796U in the single 16S rRNA operon of this organism (Mankin, 1997). 
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Fusidic acid 
Fusidic acid is an antibiotic that was isolated from the fungus Fusidium 
conccineum (Godtfredsen et al., 1962). Fusidic acid is a steroidal compound 
with a tetracyclic triterpenoid structure (Godtfredsen et al., 1965). It affects 
Gram-positive bacteria and is licensed for treatment of staphylococcal in-
fections in Europe and Australia since the 1960s (Farrell et al., 2011). The drug 
has been noted for its good oral absorption, low toxicity and low probability for 
development of cross-resistance with other antibiotics (Kirst, 2014). Fusidic 
acid inhibits translocation phase of prokaryotic translation via interfering with 
the function of EF-G. The drug binds to EF-G:GTP in complex with the ribo-
some (Bodley et al., 1969). Free EF-G has a low affinity for fusidic acid, 
indicating that a specific EF-G conformation is needed for binding (Wilson, 
2009). Cryo-electron microscopy studies of T. thermophilus ribosome revealed 
that fusidic acid binds into a pocket between domains I, II and III of EF-G (Gao 
et al., 2009). EF-G-induced GTP hydrolysis is not prevented in the presence of 
fusidic acid. Instead, the drug stabilizes the complex after GTP hydrolysis and 
translocation event (Seo et al., 2006). Fusidic acid traps EF-G on the ribosome 
in a conformation intermediate between the GTP and GDP forms (Gao et al., 
2009). As an outcome, the elongation cycle discontinues and translation process 
is hampered. The main mechanism of resistance to fusidic acid is due to point 
mutations in fusA gene that encodes EF-G (O’Neill et al., 2004). Some 
alternations in ribosomal protein L6 are also associated with resistance to the 
drug (Norstrom et al., 2007). In addition, several protective proteins such as 
FusB and FusC have been identified that bind EF-G and protect translational 
apparatus from inhibition by fusidic acid (O’Neill and Chopra, 2006; O’Neill et 
al., 2007). 
 
Edeines 
Edeines are a class of universal translation inhibitors produced by Bacillus 
brevis strain Vm4 (Kurylo-Borowska, 1959). The producer strain generates 
different edeine variants during biosynthesis, including edeines A, B, D and F. 
Each of those compounds exists as two isomers – an active α isomer and an 
inactive β isomer (Borowski et al., 1966; Czajgucki et al., 2006). Edeines are 
broad-spectrum antibiotics and affect the growth of both Gram-positive and 
Gram-negative bacteria as well as yeasts, molds and mycoplasma (Gale et al., 
1981). However, they are unsuitable for the use as clinically relevant anti-
microbial agents due to high toxicity to eukaryotic systems. Edeines are closely 
related pentapeptide amides composed of glycine, polyamine and four non-
protein amino acids (Czajgucki et al., 2006). Edeines are inhibitors of trans-
lation initiation phase. Early data indicated that edeines inhibit poly(U)-directed 
binding of Phe-tRNA to ribosomes, while no inhibiting effect was seen on 
extension of peptides (Hierowski and Kurylo-Borowska, 1965; Obrig et al., 
1971). Further experiments confirmed that edeine inhibits mRNA-directed 
binding of aminoacyl-tRNA to the 30S subunits and 70S ribosomes but does not 
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affect binding of aminoacyl-tRNA to the 70S ribosomes in the absence of 
mRNA (Dinos et al., 2004). The biding site of edeine is located on the 30S 
subunit, near the E-site where the drug interacts with 16S rRNA helices 24, 28, 
44 and 45 (Pioletti et al., 2001). Edeine blocks interaction between the 
anticodon of initiator-tRNA and the start codon of mRNA (Wilson, 2009). 
Edeines are also known as effective inhibitors of DNA biosynthesis (Kuryło-
Borowska and Szer, 1972). The edeine producer strain protects itself by rapidly 
releasing active edeine isoform to the growth medium and by only maintaining 
low concentrations of inactive edeine in the cells (Kurylo-Borowska, 1975). A 
mutant of S. cerevisiae has been isolated in which edeine effect is abolished due 
to increased affinity of 30S subunit for mRNA (Herrera et al., 1984). 
 
Cycloheximide 
Cycloheximide is a eukaryotic-specific translation inhibitor. It was originally 
isolated from Streptomyces griseus (Whiffen, 1947) and reported to inhibit 
protein synthesis in yeast (Kerridge, 1958). Cycloheximide molecule contains a 
glutarimide moiety. Studies of cycloheximide biosynthesis revealed that the 
molecule is formed by condensation of five acetate units and one malonamide 
unit and the methyl groups of a dimethylcyclohexanone ring are formed by 
transmethylation reactions (Vanek and Vondracek, 1965). 
Cycloheximide is one of the most common laboratory reagents used to block 
protein synthesis. It is rutinely used to avoid new synthesis of proteins in cell 
signaling and degradation studies. It also has an instrumental role in ribosome 
profiling experiments (Ingolia et al., 2009) and can be used as an experimental 
tool to determine the half-life of proteins. Moreover, it is used as a plant growth 
regulator and a fungicide (Milenkovski et al., 2010). 
The precise position of cycloheximide binding site remained unclear for a 
long time due to lack of structural information. Footprinting experiments revealed 
protection of an rRNA nucleotide C3993 in the E-site of 60S ribosomal subunit 
(Schneider-Poetsch et al., 2010). A structure of the 60S ribosomal subunit from 
the unicellular ciliate Tetrahymena thermophila cocrystallized with cyclo-
heximide did not unambiguously assign the orientation of the drug molecule. 
Nevertheless, the structure analysis confirmed that cycloheximide binds in a 
tight pocket on the 60S subunit that was previously identified as the binding site 
for nucleotides C75 and A76 of E-site tRNA (Klinge et al., 2011). An X-ray 
study of high-resolution structure of Saccharomyces cerevisiae 80S ribosome 
positioned cycloheximide to the E-site, into a pocket formed by the 25S rRNA 
and a stretch of the protein L42 (Garreau de Loubresse et al., 2014).  
Cycloheximide inhibits the eEF2-mediated translocation of eukaryotic trans-
lation by skewing the binding of deacylated tRNA to the E-site. Translocation 
stalls only if the E-site is occupied by both cycloheximide and deacylated tRNA 
and binding of cycloheximide alone to the E-site does not affect translocation. 
Cycloheximide shares the same binding site with lactimidomycin which is 
another glutarimide-containing antibiotic. Although both compete with the 
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binding of the tRNA CCA-end in the E-site, they affect translation in a different 
way. Lactimidomycin arrests ribosomes at the first peptide bond, while cyclo-
heximide stalls ribosomes during ongoing translation (Schneider-Poetsch et al., 
2010). 
Although most eukaryotic cells are sensitive to cycloheximide, naturally 
occurring resistance is widespread amongst yeast species because they possess 
a cycloheximide-resistant ribosome. Resistance has been shown to arise from 
the single proline substitution in a gene encoding for ribosomal protein L42 
(formerly L41) or from amino acid replacement in ribosomal protein L29 
(Dehoux et al., 1993; Stocklein et al., 1981). In addition, monomethylation at a 
single lysine in the gene encoding for L42 is associated with decreased 
susceptibility to cycloheximide (Shirai et al., 2010). 
 
New and interesting translation inhibitors 
With bacterial resistance becoming a threat to public health, there is a demand 
for new chemical scaffolds that interact with new ribosomal sites and inhibit 
translation via novel mechanisms of action. Recent years have faced the gaining 
interest towards antimicrobial peptides (AMPs) as potential therapeutics against 
antibiotic-resistant bacteria (Li et al., 2014). AMPs represent a diverse group of 
molecules that form part of the innate immune response of a variety of inver-
tebrate, plant and animal species (Brogden, 2005). Proline-rich antimicrobial 
peptides (PrAMPs) represent a group of AMPs that were identified in the late 
1980s independently in honeybees (Casteels et al., 1989) and cattle (Gennaro et 
al., 1989). Many AMPs kill bacteria by disrupting their cell membrane, whereas 
some are transported inside the bacterial cell where they bind and inactivate 
specific targets, including the bacterial ribosome. A study of the crystal struc-
tures of Thermus thermophilus 70S ribosome in complex with the PrAMPs 
Bac71–35, pyrrhocoricin, metalnikowin and two oncocin derivatives revealed that 
these peptides share a common mechanism of action. The N-terminal domain of 
ribosome-bound PrAMPs interferes with the simultaneous binding of the CCA-
end of aminoacyl-tRNA in the A-site. Therefore, binding of PrAMPs allows 
70S initiation complex formation, but prevents subsequent rounds of translation 
elongation (Seefeldt et al., 2015). The variable C-terminal regions extend to the 
ribosome exit tunnel and overlap with the binding site of macrolide and strepto-
gramin B antibiotics. The conserved middle part of each of the studied PrAMPs 
forms interactions with the elements of the ribosome that are known to be the 
binding site for several antibiotics, including chloramphenicol (Gagnon et al., 
2016). PrAMPs are synthesized on ribosomes as inactive precursors, which 
undergo proteolysis to release the active peptide. The mammalian-derived Bac7 
peptide inhibits also eukaryotic translation. To avoid self-toxifcation, the Bac7 
precursor is activated by a protease upon fusion with the phagosome or during 
exocytosis and release into the extracellular matrix where it can attack the 
bacteria (Scocchi et al., 1992; Seefeldt et al., 2016).  
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Negamycin is a natural peptide-like antibiotic. It was originally isolated 
from Streptomyces strains (Hamada et al., 1970). Negamycin exhibits inhibitory 
activity against Gram-negative and Gram-positive bacteria but its binding site 
and mode of action remained unknown for more than four decades. The 
structure of the Thermus thermophilus ribosome in complex with negamycin 
revealed that the drug binds to both small and large ribosomal subunits at nine 
independent sites. The primary site of antibiotic action was identified in the 
vicinity of the 16S rRNA helix 34 where it overlaps with the binding site of 
tetracycline. Negamycin contacts simultaneously with the 16S rRNA as well as 
the anticodon loop of the A-site-bound aminoacyl-tRNA. This antibiotic 
stimulates tRNA binding and, thus, inhibits translocation and induces miscoding 
(Polikanov et al., 2014b). 
Amicoumacin A is produced by several bacterial species isolated from both 
soil and marine environments and the antibacterial properties of this compond 
were discovered already decades ago (Itoh et al., 1981). However, the mechanism 
of action of amicoumacin A remained unknown until the year 2014 when the 
crystal structure of bacterial ribosome in complex with the drug was solved. It 
was discovered that the antibiotic makes contacts with helix 24 of 16S rRNA in 
the E site. In addition, amicoumacin A interacts also with the mRNA backbone 
suggesting that the drug interferes with translocation by stabilizing mRNA 
interaction with the small ribosomal subunit (Polikanov et al., 2014a). The 
binding site of amicoumacin A overlaps with the binding sites of three chemi-
cally unrelated antibiotics pactamycin, kasugamycin and edeine B. This feature 
could be used for designing new antibiotic hybrids with potentially superior 
antibacterial properties. 
 
 
1.2. Emerging antibiotics 
Active use of antibiotics has evoked a wide distribution of drug-resistant bacteria. 
One plausible way to overcome this concern is the development and launching 
of new antibiotics. However, this approach is decelerated by the high cost of 
necessary research. Since the year 2000, 30 new antibiotics have been launched 
worldwide. It is self-evident that development of novel antibiotics can be ob-
structed by various problems. A number of drug candidates have been dis-
continued from clinical development even after completing Phase I or Phase II 
trials (Butler et al., 2016). On the other hand, there are some cases where 
continuous research has solved unexpected problems in the course of time. One 
fitting example is the development of oxazolidinones as it took more than 20 
years until the first member of this class – linezolid – was approved for clinical 
use (Shaw and Barbachyn, 2011). The following chapters focus on three 
emerging antimicrobials and describe some difficulties that have impeded their 
launching. These antimicrobials are: (1) evernimicin, a member of orthosomycine 
class of antibiotics, (2) tiamulin, a representative of the pleuromutilin class, and 
(3) a nitrovinylfuran derivative Furvina®, also known as G1 compound.   
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1.2.1. Evernimicin 
Evernimicin is a prominent example of everninomicin group belonging to ortho-
somycine class of antibiotics. Other members of orthosomycine class include 
avilamycin, curamycin and olivamycin. Evernimicin is a highly modified octa-
saccharide produced by actinomycete Micromonospora carbonacea (Weinstein 
et al., 1964). The unique structural features of evernimicin molecule are the 
presence of a nitrosugar L-evernitrose and two acid sensitive orthoester linkages 
between carbohydrate residues (Ganguly et al., 1997). Investigations identified 
evernimicin to be active against a number of Gram-positive bacteria, including 
methicillin-resistant staphylococci and vancomycin-resistant enterococci (Jones 
and Barrett, 1995). Evernimicin also inhibits in vitro protein synthesis with 
ribosomes derived from E. coli, although wild-type E. coli cells are naturally 
resistant to the compound (McNicholas et al., 2000). 
Orthosomycins are the class of antibiotics that interact with the unique 
region of 50S ribosomal subunit. The binding site of evernimicin is located in 
the vicinity of L16, 50Å away from the PTC (Wilson, 2009). Other known 
translation inhibiting antibiotics do not compete with evernimicin for ribosome 
binding (McNicholas et al., 2000). Evernimicin protected a set of adenine 
residues in the helix 89 (A2468, A2469, A2476, A2478, and A2482) as well as 
A2534 in the helix 91 of 23S rRNA in chemical footprinting experiments (Belova 
et al., 2001). The loops of helices 89 and 91 of 23S rRNA are conserved between 
Bacteria and Archaea. The cryo-EM structure of evernimicin in complex with 
the E. coli 70S ribosome revealed that the heptasaccharide core of the drug spans 
across the minor grooves of H89 and H91, whereas the terminal dichloro-ring 
interacts with the arginine residues of ribosomal protein L16. The binding 
position overlaps with the elbow region of a tRNA bound in the A-site (Arenz 
et al., 2016).  
Early studies indicated that evernimicin interferes with the translation 
initiation. 23S rRNA helices 89 and 91 that interact with evernimicin are known 
to be essential for the function of IF2 (La Teana et al., 2001; Burakowskii et al., 
2007). Observations suggest that evernimicin interferes with the binding of IF2 
on the 50S ribosomal subunit therefore perturbing the formation of 70S pre-
initiation complex (Belova et al., 2001). Later studies indicated that evernimicin 
can also inhibit translation elongation (Orelle et al., 2013). According to a 
model, evernimicin allows initial binding of aa-tRNA at the A-site, but prevents 
complete accommodation of the incoming aa-tRNA, thus inhibiting translation 
elongation (Arenz et al., 2016). However, this model has not yet been con-
clusively demonstrated. Evernimicin does not interfere with the puromycin 
reaction (Belova et al., 2001; Arenz et al., 2016). 
Though the initial screenings did not reveal any bacterial isolates displaying 
resistance to evernimicin (Jones and Barrett, 1995), several resistance cases 
were later reported. Evernimicin-resistant Streptococcus pneumonia strains 
were found to bear mutations in rplP gene encoding the ribosomal protein L16 
or in domain V of 23S rRNA (positions 2456–2485) (Adrian et al., 2000a; 
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Adrian et al., 2000b). Resistance to the drug is achievable also via enzymatic 
modification. An rRNA methyltransferase EmtA causes reduction in evernimicin 
binding by methylating G2470 in the helix 89 of 23S rRNA (Mann et al., 2001). 
23S rRNA methylation and rplP mutants can also provide resistance to 
avilamycin, whose molecule differs from evernimycin by the absence of nitro-
sugar moiety. The extensive use of avilamycin as an animal growth promotant 
might explain the fast appearance of evernimicin resistance (Aarestrup and 
Jensen, 2000; Mann et al., 2001). 
Evernimicin was initially considered a promising therapeutic agent as it was 
active against Gram-positive pathogens resistant to clinically used antibiotics 
and cross-resistance to other drugs was not observed. Therefore, a pharma-
ceutical company Schering-Plough started development of evernimicin under 
the name Ziracin. However, the development of evernimicin was terminated 
during Phase III clinical trials in year 2000. According to press release by 
Schering-Plough, the balance between efficacy and safety did not justify further 
development. Later studies have associated administration of the drug with 
undesirable side effects. As observed in studies with rats, Ziracin caused 
anomalies of the external genitalia in F1 females along with the decreased 
reproductive performance (Poulet et al., 2005). Nevertheless, the lack of cross-
resistance between evernimicin and other ribosome-targeting antibiotics leaves 
the orthosomycins attractive for further studies. 
 
 
1.2.2. Tiamulin 
Tiamulin (Figure 13) is a member of pleuromutilin class of antibiotics. The 
parent compound of this group was discovered in 1951 and was named pleuro-
mutilin because it was isolated from an edible mushroom Pleurotis mutilus 
(later renamed Clitopilus scyphoides). A related basidomycete Pleurotis passec-
kerianus (now classified as Clitopilus passeckerianus) is another producer of 
pleuromutilin (Kavanagh et al., 1951, Knauseder and Brandl, 1976).  
Early studies of pleuromutilin demonstrated its antimicrobial activity against 
Gram-positive cocci and modest activity against a number of Gram-negative 
pathogens (Anchel, 1952). Subsequently, the compound was shown to inhibit 
the growth of penicillin- and streptomycin-resistant staphylococci as well as 
Mycoplasma (Knauseder and Brandl, 1976). Therefore, pleuromutilin gained 
the attention of Switzerland pharmaceutical company Sandoz whose researchers 
attempted to improve its antibacterial properties. Experimentations leaded to the 
discovery of semi-synthetic derivate tiamulin in 1974. Tiamulin is active against 
anaerobic bacteria, intestinal spirochetes and Mycoplasma. Still, some Gram-
negative bacteria like Pseudomonas aeruginosa and Proteus are naturally 
resistant to tiamulin (Drews et al., 1975).  
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Figure 13. The structure of tiamulin.  
 
Molecules of pleuromutilin class display an unusual structure among anti-
biotics. They possess a fused 5-6-8-membered tricyclidic diterpenoid structure 
with a C14 glycolic acid side chain (Figure 13). Chemical modification of the 
C14 side chain can alter the properties of the drug, such as the antibacterial 
activity, solubility in water and metabolism (Egger and Reinshagen, 1976; Lolk 
et al., 2008). Therefore, this side chain has been an object for a numerous 
modifications. 
Tiamulin is a strong inhibitor of bacterial peptidyl transferase reaction, but it 
is unable to bind to mammalian ribosomes (Hogenauer, 1975). The compound 
prevents the correct positioning of CCA end of tRNA to the PTC and interferes 
with peptide bond formation. Chemical footprinting experiments showed that 
tiamulin interacts with the domain V of 23S rRNA (Poulsen et al., 2001). 
Crystal structure of tiamulin in complex with 50S subunit from D. radiodurans 
revealed that tiamulin binds to the PTC, overlapping both A- and P-site tRNA 
substrates (Schlunzen et al., 2004). The binding site of tiamulin overlaps those 
of chloramphenicol and clindamycin. Tricyclic mutilin core is located inside a 
pocket confined by residues of the A-site (G2061, A2451, C2452, A2503, 
U2504, G2505 and U2506). C14 side chain points toward the P-site and 
hydrogen bonds with G2061. Binding of pleuromutilins triggers an induced fit 
that leads to conformational change concerning nucleotides U2506 and U2585. 
As a result, the movement of tRNA 3’ end from the A-site to the P-site is 
hampered due to nonproductive conformation of U2585 (Davidovich et al., 
2007; Novak and Shlaes, 2010). Pleuromutilins partially destabilize fMet-tRNA 
binding during formation of the initiation complex (Yan et al., 2006). Based on 
this data, it has been suggested that tiamulin inhibits primarily translation 
initiation rather than elongation (Novak, 2011). 
Resistance to tiamulin is shown to develop relatively slowly in vitro 
(Karlsson et al., 2001). Nevertheless, several cases of reduced susceptibility 
have been reported (Gentry et al., 2007). Reduced binding of tiamulin to the 
ribosome has been associated with point mutations in ribosomal protein L3 
(E. coli positions 148 and 149) in combination with mutations in 23S rRNA 
(nucleotides G2032, G2055, G2447, C2499, U2504 or A2572) (Pringle et al., 
2004). There is a chance for the emergence of cross-resistance between pleuro-
mutilins and other antibiotics attacking the PTC. This phenomenon can be 
mediated by Cfr methyltransferase that methylates 23S rRNA nucleotide A2503 
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located within the PTC. In addition to pleuromutilins, Cfr activity confers 
resistance also to phenicols, lincosamides, oxazolidinones, 16-membered 
macrolides and streptogramin B (Long et al., 2006).  
Tiamulin was approved in 1979 as a prophylactic and therapeutic agent for 
swine dysentery. However, initial efforts of developing pleuromutilin anti-
biotics suitable for human use encountered several problems. For instance, oral 
bioavailability of tiamulin is limited because it is rapidly metabolized by cyto-
chrome P450 metabolism (Phillips and Sharaf, 2007). Azamulin is another 
derivative that was designed for human use and demonstrated good activity 
against many clinical isolates (Hildebrandt et al., 1982). Azamulin entered into 
Phase I clinical trials on volunteers, but further studies were terminated due to 
unsatisfactory pharmacokinetics. 
In 2007, retapamulin was approved for the treatment of certain human skin 
infections (Novak and Shlaes, 2010). Thus, it took almost six decades until the 
first pleuromutilin antibiotic became available for human treatment. Some 
promising pleuromutilin derivatives are currently investigated at Nabriva Thera-
peutics (Paukner and Riedl, 2016). These new derivatives exhibit potent anti-
bacterial activity, good pharmacokinetics and excellent safety profile. One such 
compound, lefamulin, was tested successfully in a Phase II clinical trial in 2011 
(Prince et al., 2013).  
 
 
1.2.3. G1 (Furvina®) 
G1, also known by the trade name Furvina®, is a synthetic nitrovinylfuran (2-
bromo-5-(2-bromo-2-nitrovinyl)-furan). G1 is a furylethylenic derivative in 
which the nitro group is not attached to the furan ring. The compound was 
developed in Cuba by researchers at the University of Las Villas. Early experi-
ments demonstrated that nitrovinylfuran derivatives inhibit algal and yeast 
growth (Drobnica and Sturdik, 1980). Microbroth dilution tests confirmed anti-
bacterial activity of G1 against Gram-positive and Gram-negative bacteria, 
yeasts, dermatophytes and filamentous fungi (Blondeau et al., 1999). The 
compound was approved in Cuba as an ointment for the treatment of dermato-
logical infections despite of uncertain mode of action.  
The exact mechanism of action of the drug is a subject of disputation. Early 
experiments demonstrated that vinylfurans inhibit various enzymes by chemi-
cally modifying functional thiol groups in their structures (Drobnica et al., 
1981). Since then, two independent attempts have been made to elucidate the 
targets of G1. Scholz and colleagues showed that G1 inhibits the activity of 
E. coli MurA, an enzyme that catalyzes the assembly of peptidoglycan, and is 
also a potent inhibitor of bacterial methionine aminopeptidase (Scholz et al., 
2012). Both enzymes contain exposed cysteine residues at their activity sites. 
G1 did not affect the activity of MurA in which the exposed cysteine was 
replaced by aspartic acid. It was concluded that G1 is reactive towards cysteine 
residues in proteins and participates in formation of non-native disulfide bonds, 
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thereby impairing stability and catalytic properties of proteins. The authors 
emphasized that the cytotoxic activity of G1 against human cell lines is 
significant and does not encourage further development of the compound as an 
antibacterial drug (Scholz et al., 2012). 
In contrast, Fabbretti and coworkers studied the effects of G1 on prokaryotic 
translation (Fabbretti et al., 2012). In vitro translation test demonstrated that G1 
effectively inhibits translation of natural-like mRNAs in a cell-free system. 
However, G1 did not inhibit poly(U)-dependent poly(Phe) synthesis and did not 
cause mRNA misreading, suggesting that G1 is not an inhibitor of translation 
elongation phase. Further experiments showed that G1 binds to 30S ribosomal 
subunits and competes with fMet-tRNA for the same binding site. IF2:GTP-
dependent binding was not affected by G1. Hydroxyl radical cleavage and 
primer extension analysis revealed that G1 induces conformational changes at 
16S rRNA site affecting the P-decoding region of the 30S subunit. Based on 
this data, it was reasonable to conclude that G1 is a translation inhibitor that 
binds to the 30S ribosomal subunit and inhibits P-site decoding thereby blocking 
formation of 30S initiation complex (Fabbretti et al., 2012). 
 
 
1.3. General mechanisms of antibiotic resistance 
1.3.1. Efflux 
Bacteria are using efflux systems in order to export certain chemical substances 
out of their cells. Efflux is mediated by membrane-associated proteinaceous 
transporters that function as pumps. Efflux systems in Gram-positive bacteria 
compose of a single transmembrane polypeptide. On the other hand, certain 
pumps found in Gram-negative organisms exist as a tripartite system, spanning 
both the inner and outer membrane (Li and Nikaido, 2008).  
First descriptions of efflux mechanisms derive from the studies of tetra-
cycline-resistant E. coli (Ball et al., 1980; McMurry et al., 1980). Other types of 
efflux systems were discovered and characterized during next years (Poole et 
al., 1993; Paulsen et al., 1996). Some efflux systems are specific to a certain 
drug while others are able to export structurally different antimicrobials and are 
therefore called multidrug efflux systems (Saier et al., 1998). Genes encoding 
components of efflux systems can be located on the chromosome or on mobile 
genetic elements. Chromosomally encoded pumps can explain the inherent 
resistance of some bacterial species to a particular antibiotic (Munita and Arias, 
2016). When present on plasmids or transposons, these genes facilitate the 
spread of antibiotic resistance. Today, efflux is considered to be one of the 
major determinants associated with the multidrug resistance (Lewis, 1994; Sun 
et al., 2014). 
Efflux systems are thought to be widespread in bacteria already before the 
beginning of the antibiotic era (Saier et al., 1998). The pumps respond to a 
variety of stimuli and may perform different physiological functions in addition 
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to conferring drug resistance. For instance, efflux systems have been associated 
with the export of various toxic substances that are present in the environment 
(Piddock, 2006a; Poole, 2008; Thanassi et al., 1997). Efflux has also been shown 
to be involved in the secretion of quorum-sensing signals (Amaral and Molnar, 
2012). 
Efflux process is energy-dependent. Most of bacterial efflux systems are 
antiporters that use energy generated by difference of electrochemical potentials 
across the membrane. In such case, efflux process is coupled to the influx of 
protons or sodium ions (Figure 14). However, pumps belonging to the ABC 
family use the energy derived from ATP hydrolysis (Shlykov et al., 2013). 
Five classes of efflux systems are implicated in the resistance to antibiotics 
(Figure 14). Classification of pumps is based on their structural characteristics 
as well as their energy source (Piddock, 2006b). 
 
 
 
Figure 14. Schematic illustration of the main classes of bacterial efflux systems: the 
multidrug and toxic compound extrusion (MATE) family, the major facilitator super-
family (MFS), the small multidrug resistance (SMR) family, the adenosine triphosphate 
(ATP)-binding cassette (ABC) superfamily and the resistance-nodulation-division 
(RND) family. IM: inner membrane. OM: outer membrane. OMP: outer membrane 
protein. 
 
 
Major facilitator superfamily (MFS) 
MFS transporters constitute an ancient family and they are widespread in both 
Gram-negative and Gram-positive organisms. Members of this family are 
proton-driven antiporters. Their structure is composed of either 12 or 14 
membrane-spanning helices (Saidijam et al., 2006). Substrates of MFS family 
include various biocides and dyes as well as antibiotics tetracycline, chlor-
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amphenicol, macrolides and fluoroquinolones. Examples of this group include 
tetracycline-specific pumps Tet(K) and Tet(L). Nearly 30 tet genes are known 
that are related to efflux and most of them are found in mobile genetic elements. 
These pumps often decrease tetracycline and doxycycline susceptibility but do 
not expel the third generation tetracycline tigecycline (Roberts, 2005). 
 
Small multidrug resistance (SMR) family 
SMR transporters were first discovered in Gram-positive S. aureus (Tennent et 
al., 1989). Subsequently they were also identified in Gram-negative bacteria and 
archaea (Bay et al., 2008). This group comprises small transport proteins that 
contain 4 transmembrane segments and often form tetramers in the cytoplasmic 
membrane. SMR transporters are drug-proton antiporters. SMR transporters were 
found to be implicated in reduced susceptibility to biocides (Littlejohn et al., 
1992). AbeS from Acinetobacter baumannii is one of few SMR pumps related 
to resistance to fluoroquinolones, chloramphenicol and erythromycin (Srini-
vasan et al., 2009). 
 
Resistance-nodulation-division (RND) family 
RND pumps usually exist as a complex composed of three components: (1) an 
inner membrane pump that consists of 12 transmembrane helices and uses the 
proton motive force for extruding the substrates, (2) a membrane fusion protein 
located in the periplasmic space, and (3) an outer membrane protein that forms 
a channel in the outer membrane and acts as an efflux duct (Zgurskaya and 
Nikaido, 1999). Each of these three components is essential for drug efflux and 
the absence of even one component makes the entire complex nonfunctional 
(Ma et al., 1995). One of the best studied tripartite drug effux complexes is the 
AcrA-AcrB-TolC transporter from E. coli (Du et al., 2014). TolC can also 
function with other types of efflux machinery (Hinchliffe et al., 2013). Due to 
construction of RND pumps, the drugs are transported directly into the external 
medium (Nikaido, 1996). Substrate specificity of RND pumps can be re-
markably wide.  
Many Gram-negative bacteria are resistant to β-lactams, macrolides and 
linezolid due to RND efflux systems (Blair and Piddock, 2009). In addition, RND 
pumps are responsible for removing other toxic substances (bile salts, dyes, 
disinfectants) from the cell. These pumps are not exclusive to Gram-negative 
bacteria, as some Gram-positive organisms are found to possess genes encoding 
proteins with structural characteristics of RND pump monomers (Schindler et 
al., 2015). 
 
Multidrug and toxic compound extrusion (MATE) family 
These pumps were the last discovered and are found in both Gram-negative and 
Gram-positive bacteria (Kuroda and Tsuchiya, 2009). MATE transporters are 
composed of 12 transmembrane regions and they share structural similarities 
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with MFS transporters. However, amino acid sequences of the two families are 
quite different. Moreover, MATE transporters often use Na+ gradient as an 
energy source instead of proton gradient (Morita et al., 2000). VcmB and VcmD 
are examples of this class that reduce susceptibility to aminoglycosides, fluoro-
quinolones and cationic compounds in Vibrio cholerae (Begum et al., 2005). 
 
ATP-binding cassette (ABC) superfamily 
Transporters belonging to this family are rare and they offer rather modest level 
of resistance. However, they can transport various substrates including sugars, 
amino acids, polysaccharides and drugs like macrolides, fluoroquinolones and 
tetracyclines (Fernandez and Hancock, 2012). ABC transporters are either 
homodimers or heterodimers and they utilize the energy derived from the ATP 
hydrolysis (Moussatova et al., 2008). These efflux systems consist of two units: 
an intracellular nucleotide-binding domain dimer, which binds and hydrolyses 
ATP, and a membrane-domain dimer, which is embedded in the membrane and 
acts as a trans-membrane pathway for substrates (Du et al., 2015; Lubelski et 
al., 2007). The first described ABC transporter was a macrolide-specific tripartite 
MacABC-TolC in E. coli (Kobayashi et al., 2001). Based on the sequence 
similarity, the ABC protein family has been divided into eight subfamilies, 
denoted by the letters A to H. Interestingly, members of the ABC-F subfamily 
lack any identifiable transmembrane domain and instead of being involved in 
transport, these proteins mediate resistance to many antibiotics that bind to the 
50S subunit of the ribosome (Sharkey et al., 2016). 
Expression of efflux genes is often very complex, involving a variety of 
transcriptional regulators and other modulators (Grkovic et al., 2002). Some 
pumps can be constitutively expressed, thus providing intrinsic resistance 
(Poole, 2005). However, expression of many efflux systems is controlled by the 
presence of at least one of their substrates in the environment. For instance, 
expression of MFS pump QacA in Staphylococcus aureus is negatively 
regulated by transcriptional repressor QacR. When QacA substrates (e.g. certain 
dyes) are present, they bind to QacR thus inactivating the repressor protein and 
enabling the expression of QacA (Grkovic et al., 1998). 
Efflux pump inhibitors (EPIs) are compounds that interfere with the function 
of efflux systems, thus increasing the drug concentration inside a cell (Zechini 
and Versace, 2009). EPIs can affect efflux systems by various ways, including 
blocking of energy required for the activity of pumps, repressing a gene 
encoding efflux pumps or interfering with the assembly of pumps (Bhardwaj 
and Mohanty, 2012). EPIs are considered as promising tools for restoring the 
activity of antibiotics that are substrates for efflux pumps. Still, none of EPIs 
has been approved for clinical use so far. 
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1.3.2. Target modifications 
Resistance to antibiotics can be conferred via alternations in their target site. 
There are two basic ways for altering the drug binding site: (1) by mutations in 
genes encoding ribosomal RNA or ribosomal proteins, and (2) by enzymatic 
modifications of rRNA nucleotides that comprise the drug binding site. Another 
possibility for avoiding the antimicrobial action is to “bypass” the metabolic 
pathway they inhibit by overproducing the antimicrobial target (Munita and 
Arias, 2016). 
The binding sites of most of ribosome-targeting antibiotics are composed 
exclusively or primarily of rRNA. Mutations in rRNA sequence may alter the 
conformation of antibiotic binding site and result in resistance to these anti-
biotics. The presence of low antibiotic levels in the environment contributes to 
the appearance of mutations conferring antibiotic resistance (Hughes and 
Andersson, 2012). The binding sites of many clinically used antibiotics are 
located at the decoding site of the ribosome or at the PTC (Figure 1), which are 
critical regions for ribosome function. Thus, mutations in rRNA may interfere 
with ribosome function and mutations conferring resistance to antibiotics are 
often accompanied by fitness cost to the cell. In several cases, fitness cost can 
be overcome by compensatory mutations (Bjorkman and Andersson, 2000; 
Schrag and Perrot, 1996). For instance, fitness cost of G2576T transversion in 
23S rRNA conferring resistance to linezolid can be relieved by mutations in 
ribosomal proteins L3 and L16 (Billal et al., 2011). Moreover, resistant cells 
possessing compensatory mutations may be more fit than susceptible cells 
carrying the same compensatory mutants (Schrag et al., 1997). This might 
explain why some mutational resistance can be maintained stably in the absence 
of antibiotic use (Woodford and Ellington, 2007). 
Direct interactions between antibiotics and ribosomal proteins are rare. 
Nevertheless, resistance to antibiotics can be caused by mutations in ribosomal 
proteins. Alternations in proteins cause resistance indirectly by perturbing the 
conformation of rRNA. Well-known examples are mutations in protein L3 that 
can render cells resistant to pleuromutilins despite of the lack of direct 
interaction with the drug (Pringle et al., 2004). Alternations in ribosomal protein 
L22 can render ribosomes resistant to erythromycin, in some cases even without 
reducing their affinity to the drug (Chittum and Champney, 1994; Tu et al., 
2005). Sometimes the susceptibility to antibiotics is reduced by the combination 
of both ribosomal protein and rRNA mutations (LaMarre et al., 2013). 
In most bacteria, rRNA is encoded by multiple operons. A mutation has to be 
present in all or in a majority of rRNA operons to achieve high-level resistance. 
Therefore, enzymatic modification of rRNA is a more common resistance 
mechanism. rRNA methyltransferase Cfr methylates the C8 position of the 
conserved nucleotide A2503 of the 23S rRNA (Kehrenberg et al., 2005). 
Methylation of A2503 occurs during ribosomal assembly (Yan et al., 2010). As 
A2503 is located in the cavity of the peptidyl transferase site of the ribosome, 
its methylation perturbs the positioning of antibiotics that target the PTC. Cfr-
51 
mediated modification of A2503 gives rise to PhLOPSA phenotype that is 
resistant to phenicols, lincosamides, oxazolidinones, pleuromutilins and strepto-
gramin A antibiotics (Long et al., 2006). Furthermore, Cfr also provides 
resistance to 16-member-ring macrolides (Smith and Mankin, 2008). The 
respective cfr gene was originally discovered in Staphylococcus sciuri isolates of 
animal origin (Schwarz et al., 2000). Experiments with the laboratory S. aureus 
strains revealed that only a slight fitness cost can be associated with cfr 
acquisition (LaMarre et al., 2011). This observation can explain the apparent 
spread of the cfr gene among pathogens. 
Erm methyltransferases add one or two methyl groups to the N6 position of 
A2058 of 23S rRNA (Skinner and Cundliffe, 1982). A2058 is located inside of 
the nascent peptide exit tunnel that concurrently serves as a macrolide binding 
site (Hansen et al., 2002). Monomethylation disturbs the conformation of 
A2058 and confers high resistance to licosamides and moderate resistance to 
macrolides and streptogramin B antibiotics. Dimethylation of A2058 results in 
MLSB phenotype, which demonstrates high resistance to lincosamides, 
steptogramin B antibiotics and macrolides including ketolide telithromycin 
(Weisblum, 1995a). 
Currently, there are 40 known erm genes (http://faculty.washington.edu/ 
marilynr). The erm(B) and erm(F) genes have the widest host range as they 
have been found in more than 20 different genera. Expression of erm genes is 
often regulated posttranscriptionally by translation attenuation and induced only 
when antibiotic is present (Weisblum, 1995b; Ramu et al., 2009). Nevertheless, 
several clinical isolates with mutated attenuator have been reported in which 
erm genes are expressed constitutively (Depardieu et al., 2007). 
In contrast to the Cfr methyltransferases, expression of the ErmC methyl-
transferases causes reduction in cell fitness. Alternation of A2058 structure 
results in abnormal interactions between the nascent peptide and ribosomal exit 
tunnel. This observation explains why erm genes have evolved to be inducible 
(Gupta et al., 2013). 
Methyltransferases conferring resistance to aminoglycosides form the RMA 
(Resistance Methyltransferases for Aminoglycosides) superfamily. RMAs 
provide intrinsic or acquired resistance to aminoglycosides by modifying either 
nucleotide G1405 or A1408 in the A-site of the 30S ribosomal subunit. RMAs 
found in natural aminoglycoside producers can be divided into two groups. 
Members of Kgm subfamily modify the N7 position of G1405 of 16S rRNA 
and confer high-level resistance to 4,6-DOS (Savic et al., 2009). Members of 
Kam subfamily act at the N1 position of 16S rRNA nucleotide A1408 and confer 
resistance to kanamycin and tobramycin but not to gentamicin (Beauclerk and 
Cundliffe, 1987). In addition to natural aminoglycosides-producers, several 
Gram-negative human pathogens have been found to harbor 16S rRNA 
methylase genes that methylate either G1405 or A1408 and confer high-level 
resistance to clinically useful aminoglycosides (Doi and Arakawa, 2007). 
In some cases, defective methylation can also confer resistance to antibiotics. 
The methyltransferase KsgA methylates universally conserved nucleotides 
52 
A1518 and A1519 in helix 45 of 16S ribosomal RNA. The exact biological 
function of this rRNA modification is unknown. Inactivation of the ksgA gene 
and loss of the dimethylations confers resistance to the aminoglycoside 
antibiotic kasugamycin (Helser et al., 1972; O’Farrell et al., 2008). 
 
 
1.3.3. Antibiotic modifications 
Enzymatic modification or degradation of antibiotics is a widespread bio-
chemical defense mechanism among bacteria. Enzymatic strategies of antibiotic 
inactivation involve: (1) inactivation by hydrolysis, (2) inactivation by group 
transfer and (3) inactivation by redox processes. 
 
Antibiotic inactivation by hydrolysis 
Several antibiotics contain hydrolytically susceptible chemical bonds in their 
structure. Hydrolysis is the most common resistance mechanism against β-
lactam antibiotics. These drugs contain a β-lactam ring in their structure that can 
be cleaved by enzymes called β-lactamases. However, hydrolysis also provides 
resistance to other antibiotics including marcolides and chloramphenicol. 
Macrolide esterases have been found in members of the family Entero-
bacteriaceae as well as in staphylococci (van Hoek et al., 2011). These enzymes 
catalyze the hydrolysis of macrolide lactone ring. The first gene encoding 
erythromycin esterase was discovered from E. coli and named ere(A) (Ounissi 
and Courvalin, 1985). Subsequently, ere(B) gene was isolated from another 
E. coli isolate (Arthur et al., 1986). EreB esterase can hydrolyze erythromycin 
and oleandomycin (Arthur and Courvalin, 1986). The amino acid sequences of 
EreA and EreB do not display statistically significant homology. Another 
erythromycin resistance gene designated ere(C) has been found in Klebsiella 
(Yong et al., 2009). 
 
Antibiotic inactivation by group transfer 
Bacteria are neutralizing some antibiotics by adding various functional groups to 
their molecules. These modifications include O- and N-acetylation, O-phosphory-
lation, O-nucleotidylation, O-ribosylation, O-glycosylation and thiol transfer 
(Wright, 2005). Modifications can dramatically reduce the binding affinity of 
antibiotics to their target. Group transfer reactions are catalyzed by a diverse 
family of intracellular enzymes called group transferases. These modifying 
enzymes require a co-substrate for their activity (acetyl-CoA, ATP, NAD+, etc). 
An impressive number of transferases are implicated in conferring resistance to 
aminoglycosides (Jana and Deb, 2006; Ramirez and Tolmasky, 2010). 
Aminoglycoside modifying enzymes are divided into three classes according to 
the type of modification: O-phosphotransferases (APHs), O-nucleotidyltrans-
ferases (ANTs) and N-acetyltransferases (AACs). As each transferase targets a 
specific region within an aminoglycoside molecule, these enzymes are further 
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divided into subclasses. APHs are widely distributed among bacterial patho-
gens. According to their regiospecificity, seven subclasses of APHs are dis-
tinguished. They add the γ-phosphate group derived from ATP to the hydroxyl 
moiety which is located at the position 4, 6, 9, 3’, 2’’, 3’’ or 7’’ of an amino-
glycoside molecule. ANTs adenylate hydroxyl groups of aminoglycosides at the 
6, 9, 4’, 2’’ or 3’’ positions. The ANT class has an impact on medicine as 
ANT(2’’) can modify clinically important drugs tobramycin and gentamicin 
(Miller et al., 1997). AACs use acetyl-CoA as a donor substrate and catalyze the 
acetylation of -NH2 groups at the 1, 3, 2’ or 6’ positions. A bifunctional enzyme 
AAC(6’)-APH(2’’) has been identified that is able to sequentially acetylate and 
phosphorylate its substrates (Shaw et al., 1993). 
Group transfer is also a prevalent mechanism of chloramphenicol resistance. 
Chloramphenicol acetyltransferases (CATs) are widespread in Gram-positive 
and Gram-negative bacteria. They are catalyzing the transfer of an acetyl group 
to the 3-hydroxyl group of chloramphenicol, yielding 3-O-acetyl-chlorampheni-
col (Shaw, 1967). Acetyl-coenzyme A is utilized as a donor for acetyl group. 
The acetyl group can be transferred non-enzymatically from the 3-hydroxyl 
group to the 1-hydroxyl group of chloramphenicol. As a result, 3-hydroxyl 
group becomes available for another CAT-catalyzed acetylation (Thibault et al., 
1980). Both di- and mono-acetylated chloramphenicol molecules are unable to 
bind tightly to the 50S ribosomal subunit (Bulkley et al., 2010; Shaw and 
Unowsky, 1968). In addition to chloramphenicol, CATs are able to inactivate 
thiamphenicol and azidamfenicol. Florfenicol, on the other hand, remains 
resistant to CAT because its molecule contains a fluor residue instead of the 3-
hydroxyl group (see Figure 5). 
Expression of genes encoding CATs can be constitutive or regulated by 
translational attenuation, with chloramphenicol acting as an inducer (Lovett, 
1990; Schwarz et al., 2004). Native CAT variants are usually homotrimers. 
Despite of their overall similar structure, CAT proteins can be divided into three 
classes (Foster and Shaw, 1973). Members of CATI class demonstrate high 
similarity in their amino acid sequences. However, CATI proteins share only 
modest similarity with proteins belonging to classes CATII (46 %) and CATIII 
(32–47%) (Biswas et al., 2012). CATII class differs from CATIII class through 
its extreme susceptibility to thiol-modifying agents (Murray et al., 1990). Some 
bacteria have been found to harbor so-called xenobiotic acetyltransferases that 
can also acetylate chloramphenicol, but are structurally unrelated to three CAT 
classes (Murray and Shaw, 1997). 
Chloramphenicol producer S. venezuelae lacks CAT activity (Shaw and 
Hopwood, 1976). Instead, this organism protects itself against its own toxic 
compound by harboring chloramphenicol phosphotransferase (CPT). CPT uses 
ATP as phosphoryl donor to transfer the γ-phosphate to the 3-hydroxyl group of 
chloramphenicol. Phosphoryl group is later removed by an extracellular 
phosphatase, resulting in an active antibiotic (Mosher et al., 1995). CTP does 
not show significant sequence similarity to aminoglycoside phosphotrans-
ferases. 
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Macrolide 2′-phosphotransferases [MPH(2′)] phosphorylate the 2′-hydroxyl 
group of an amino sugar in the macrolide molecule. The phosphoryl group is 
obtained from the γ-phosphate of ATP. Macrolide phosphotransferases have 
been found mainly in Gram-negative bacilli and they are divided into two 
groups. Members of MPH(2′)-I are encoded by the mph(A) and mph(D) genes 
and inactivate preferbly 14-membered ring macrolides (see Figure 4). MPH(2′)-
II enzymes, encoded by the mph(B) and mph(D) genes are able to inactivate 14- 
as well as 16-membered ring macrolides (O’Hara et al., 1989; Chesneau et al., 
2007). 
Streptomyces lividans expresses a glycosyltransferase for self-protection. 
The enzyme catalyses glycosylation of macrolides at the 2’ position and uses 
UDP-glucose as a co-factor (Jenkins and Cundliffe, 1991). However, 
glycosyltransfer is not considered a widely distributed resistance mechanism 
(Wright, 2005). 
 
Redox processes 
A few examples of resistance provided by oxidation or reduction of antibiotics 
can be found. The most prominent example of redox enzymes is Tet(X) that 
was discovered on a conjugative transposon in Bacteoides fragilis (Speer and 
Salyers, 1989). Tet(X) is a monooxygenase capable of inactivating all clinically 
relevant tetracycline antibiotics, including the third generation tetracycline 
tigecycline (Moore et al., 2005). The enzyme utilizes NADPH and O2 to add a 
hydroxyl group to the C11a position located between B and C ring of tetra-
cycline molecule. The antibiotic properties of hydroxylated tetracyclines are 
significantly reduced due to their fast degradation (Yang et al., 2004). More-
over, modified tetracyclines can only weakly bind Mg2+-ions, which are 
essential for their interaction with the ribosome (Brodersen et al., 2000; Moore 
et al., 2005). 
 
 
1.4. Target cleaning 
1.4.1. Macrolide resistance peptides 
Peptide-mediated resistance is a coincidentally discovered mechanism that con-
fers resistance to macrolide antibiotics including ketolides. First evidence of a 
novel resistance mechanism was obtained in experiments in which E. coli cells 
expressing random fragments of ribosomal RNA operon rrnB were screened for 
the presence of erythromycin-resistant clones (Tenson et al., 1996). All resistant 
clones were noticed to express rRNA fragments encompassing the region 1233–
1348 of 23S rRNA. It was found that expression of a 34 nucleotides long rRNA 
fragment (E-RNA34) corresponding to residues 1235–1268 in 23S rRNA is 
sufficient to provide a low-level resistance to erythromycin. E-RNA34 con-
tained the Shine-Dalgarno sequence, initiator and terminator codons and an 
ORF coding for a pentapeptide MRMLT (Tenson et al., 1996). 
55 
Extensive selection experiments revealed certain pentapeptide sequences (so-
called E-peptides) conferring resistance to erythromycin and other macrolides. 
Analysis of more than 70 E-peptide sequences helped to identify a consensus 
sequence fMet-(bulky/hydrophobic)-(Leu/Ile)-(hydrophobic)-Val (Tenson et al., 
1997). The E-peptide MRLFV rendered cells resistant to high concentrations of 
erythromycin and low concentrations of oleandomycin and spiramycin, but not 
to ketolides. On the other hand, the peptide MRFFV providing resistance to 
ketolide HMR 3004 did not protect cells from high concentrations of erythro-
mycin (Tripathi et al., 1998). As a fact, peptides with significantly different 
amino acid sequence are needed to confer resistance to chemically different 
macrolides and only a little cross-resistance was observed (Vimberg et al., 
2004). 
 
 
 
Figure 15. Model of action of macrolide resistance peptides. (1) Binding of a macrolide 
to the 50S ribosomal subunit hinders growth of the nascent peptide chain in the early 
rounds of protein synthesis and then exerts antibiotic activity in inhibiting protein 
biosynthesis in the elongation step. (2) Translation of a macrolide resistance peptide 
“cleans” the ribosome from antibiotic. If an antibiotic-free ribosome initiates synthesis 
of a cellular protein and polymerizes the first two to five amino acids, it will become 
“immune” to an antibiotic until the completion of polypeptide synthesis because macro-
lides cannot bind to ribosomes containing long nascent peptides. The figure is adapted 
from Verdier et al., 2002. 
 
Pentapeptides confer resistance only to a ribosome on which the peptide is 
translated. Addition of synthetic E-peptides did not influence erythromycin 
sensitivity in the cell-free translation system (Tenson et al., 1996). Based on 
experimental data, Tenson and Mankin proposed a model for explaining the 
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action of macrolide resistance peptides (Figure 15). Macrolide antibiotics do not 
inhibit polymerization of first few amino acids. Thus, the ribosome can translate 
resistance peptides also in the presence of macrolides. When synthesis of the 
resistance peptide is almost complete, the nascent peptide forms contacts with 
the drug and acts as a “bottle brush” that “cleans” the ribosome from the bound 
antibiotic. The macrolide-free ribosome can now initiate translation from a 
cellular mRNA. After polymerization of a peptide 4–6 amino acids in length, 
the ribosome becomes “immune” to macrolides until the completion of a poly-
peptide synthesis (Tenson and Mankin, 2001). 
The following experiments by Lovmar and colleagues demonstrated that 
resistance peptide can remove erythromycin from the ribosome with close to 
100% probability (Lovmar et al., 2006). Biochemical data together with com-
putational modeling suggested that the side chain of leucine in the E-peptide 
MRLFV binds to the hydrophobic cleft between the cladinose and desosamine 
moieties of erythromycin. Interaction between leucine and erythromycin in 
combination with extension of the resistance peptide weakens the affinity of the 
drug to the ribosome. However, final dissociation of erythromycin occurs not 
until class 1 release factor induces termination of the full-length resistance 
polypeptide. The determined length of resistance peptide is crucial for its 
activity as synthesis of a hexapeptide with the same five N-terminal amino acids 
leaded neither to drug ejection nor to resistance to erythromycin (Lovmar et al., 
2006).  
Expression of an rRNA-encoded pentapeptide in wild-type E. coli cells is 
unlikely to occur as its Shine-Dalgarno sequence is hidden into the 23S rRNA 
secondary structure. However, expression could be activated by site-specific 
fragmentation of rRNA or by mutations that enable the accessibility to the Shine-
Dalgarno region (Dam et al., 1996). Interestingly, a spontaneous deletion of 
positions 1219–1230 in 23S rRNA was shown to render cells resistant to 
erythromycin (Douthwaite et al., 1985). Activation of the rRNA-encoded penta-
peptide expression due to accessible ribosome-binding site can provide an 
explanation for this observation. Although further evidences are missing, 
similar mechanisms of antibiotic resistance may occur in nature. It is not clear, 
whether the presence of a functional gene in rRNA is a result of evolutionary 
selection or just a coincidence.  
 
 
1.4.2. Ribosomal protection proteins 
Various mechanisms may be responsible for the resistance to tetracyclines, in-
cluding enzymatic inactivation of the drug, mutations in rRNA and those 
mediated by efflux pumps. Ribosomal protection proteins (RPPs) confer 
resistance by a unique mechanism that was originally described in tetracycline-
resistant Streptococcus (Burdett, 1986). RPPs bind the ribosome and catalyze 
the release of tetracycline in a GTP-dependent manner. However, the release of 
tetracycline occurs also in the presence of non-hydrolyzable GTP analogues. 
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Therefore, the GTPase activity is required for the multi-turnover of RPPs rather 
than for the release of the drug (Burdett, 1996; Trieber et al., 1998). 
RPPs belong to the translation factor superfamily of GTPases (Leipe et al., 
2002) and they share 50% of sequence similarity with EF-G (Donhofer et al., 
2012). RPPs are spread among both Gram-negative and Gram-positive bacteria 
inhabiting various environments and ecosystems (van Hoek et al., 2011). So far, 
12 different classes of RPPs have been reported (http://faculty.washington.edu/ 
marilynr/). These proteins confer resistance to tetracycline, doxycycline and 
minocycline, while the third generation tetracyclines generally retain anti-
bacterial activities in the presence of RPPs (Bergeron et al., 1996; Draper et al., 
2013). Genes encoding RPPs are often located on transposons or other mobile 
genetic elements, which facilitates their spread via lateral gene transfer. 
Tet(O) and Tet(M) are the best characterized RPPs. They are soluble cyto-
plasmic proteins possessing 75% of sequence identity (Taylor and Chau, 1996). 
Tet(O) was discovered in Camphylobacter jejuni and became the first cloned 
RPP (Taylor, 1986). Tet(M) has the broadest host range among RPPs. RPPs are 
thought to be originated from otrA gene which is harbored by oxytetracycline 
producer Streptomyces rimosus (Doyle et al., 1991). Several mosaic genes have 
been identified that contain regions from 2 or 3 different tet genes. Mosaic 
genes, such as tet(O/W) are thought to arise via recombination between different 
tet genes (Stanton et al., 2005). 
Early experiments demonstrated that Tet(M) and EF-G compete for binding 
to the ribosome (Dantley et al., 1998). Subsequent studies of cryo-EM struc-
tures showed that the RPPs bind into an intersubunit space similarly to EF-G 
(Spahn et al., 2001; Donhofer et al., 2012). When bound to a ribosome, Tet(M) 
overlaps with the anticodon stem-loop of the A-tRNA and interacts with the 
helix 34 of 16S rRNA, which is a component of tetracycline binding site (Don-
hofer et al., 2012). The presence of an antibiotic thiostrepton blocks the ability 
of Tet(M) to form a stable complex with ribosomes and also inhibits GTP-
dependent tetracycline release from ribosomes (Dantley et al., 1998).  
Donhofer and colleagues studied the cryo-EM structure of the Tet(M):70S 
complex at 7.2-Å resolution and suggested that binding of Tet(M) alters the 
conformation of nucleotides C1054 and U1196 of the 16S rRNA (Donhofer et 
al., 2012). Tet(M) was thought to remove tetracycline molecule from the A-site 
by disrupting interaction between the aromatic D ring and C1054. According to 
the proposed model, immediate rebinding of the drug is inhibited as the con-
formational changes in 16S rRNA persist after dissociation of RPP from the 
ribosome (Donhofer et al., 2012). However, recent work in which Tet(M):70S 
complex was studied at 3.9 Å resolution indicated that Tet(M) does not alter the 
conformation of C1054 (Arenz et al., 2015). In addition, RPPs were shown to 
induce a flipped-out conformation of 16S rRNA nucleotides A1492 and A1493. 
Such conformation persists upon dissociation of RPP from the ribosome and 
promotes rapid binding of the aa-tRNA:EF-Tu:GTP ternary complex (Connell 
et al., 2003a; Donhofer et al., 2012). 
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Expression of Tet(M) is controlled by translational attenuation and induced 
by tetracycline molecule. The gene encoding tet(M) is preceded by a leader 
ORF. In the absence of tetracycline, the ribosome binding site of tet(M) ORF is 
hidden by mRNA secondary structure, but translation of leader ORF is enabled. 
Tetracycline is proposed to inhibit translation of tet(M) leader ORF. As an 
outcome, mRNA folds into conformation, which enables tet(M) translation 
(Lodato et al., 2006). 
The resistance mechanism provided by proteins such as Tet(O) and Tet(M) 
may, however, be not completely unique. Studies have suggested that proteins 
belonging to the ABC-F subfamily of ATP-binding cassette transporters may 
function in a similar manner. The family of ATP-binding transporters is divided 
into eight subgroups on the basis of their sequence similarity (Dean et al., 
2001). Despite of sharing homology with other members of the family, ABC-F 
proteins are not directly involved in transport (see chapter ATP-binding cassette 
(ABC) superfamily). They lack transmembrane domanis and instead they com-
prise a single polypeptide that contains two ATP-binding cassette domains (Kerr, 
2004). ABC-F proteins are found in Gram-positive bacteria where they can 
confer resistance to many antibiotic classes that bind to the 50S ribosomal 
subunit, including the macrolides, lincosamides, phenicols, oxazolidinones and 
streptogramins. However, no single protein confers resistance to every listed 
class. Resistance to lincosamides and streptogramins A is mediated by ABC-F 
proteins encoded by vga, lsa and sal genes, while msr gene products can confer 
resistance to macrolides and streptogramins B. Another ABC transporter gene, 
optrA, confers combined resistance to oxazolidinones and phenicols (Wilson, 
2016). 
Results obtained so far suggest that ABC-F proteins mediate resistance to 
antibiotics through direct interaction with the ribosome (Sharkey et al., 2016). 
The process seems to require ATP hydrolysis, since mutations in the nucleotide-
binding domain of ABC-F protein Vga(A) rendered cells susceptible to anti-
biotics (Jacquet et al., 2008). The molecular details of mechanism by which 
ABC-F proteins confer resistance are not completely understood. One possi-
bility is that the binding of ABC-F proteins physically overlaps the drug-bin-
ding sites on the ribosome. Alternatively, the binding of proteins can induce 
conformational changes in the ribosome that promote displacement of drug 
molecule.  
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2. AIMS OF THE STUDY 
I 
Several nascent polypeptide chains are able to induce translational stalling in 
response to specific ligand molecules (Weisblum, 1995b; Ramu et al., 2009; 
Gong and Yanofsky, 2002). The aim of our study was to develop a universal 
method for finding such cis-acting regulatory sequences. If the approach would 
turn out to be successful, our further goal was to characterize the identified 
sequences and shed light on the possible sequence rules. 
 
II 
Ribosomal protection proteins confer resistance to tetracycline by dislodging 
the drug from the ribosome (Burdett, 1996; Connell et al., 2003a). An atomic 
model of the ribosome-Tet(O) complex suggests that the three loops of domain 
IV of ribosomal protection protein Tet(O) play a crucial role in Tet(O)-mediated 
tetracycline resistance. The goal of current study was to validate the structural 
results by mutational analysis. For this purpose, I introduced deletions or sub-
stitution mutations into the three loops of Tet(O) domain IV and measured the 
functional activity of mutant Tet(O) variants in vivo. 
 
III 
G1 (or Furvina®) is an antimicrobial of 2-vinylfuran family. It has been shown 
to target the 30S ribosomal subunit and inhibit translation initiation (Fabbretti et 
al., 2012). On the other hand, G1 has a direct reactivity against thiol groups 
(Balaz et al., 1982). By reacting with thiol groups it causes direct damage to 
proteins but, as a result, is very short-living and interconverts into an array of 
reaction products (Scholz et al., 2013). Our aim was to characterize thiol re-
activity of G1 and identify its decomposition products. We also wanted to 
clarify how much of antimicrobial and cytotoxic effects are due to the primary 
activity of the compound and how much can be attributed to its breakdown 
products.  
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3. METHODS 
Peptide expression libraries  
A peptide expression library is a collection of plasmid expression vectors 
encoding a systematic combination of different peptides. Such libraries are 
usually generated by PCR using primers containing random nucleotides. Plasmid 
libraries expressing random peptides provide a useful tool for isolating peptides 
with various properties. For instance, a 21-codon mini-gene library together 
with a pentapeptide library was used to isolate peptides conferring resistance to 
erythromycin (Tenson et al., 1997). Similarly, a random pentapeptide mini-gene 
library was successfully applied to identify sequences conferring resistance to 
several other macrolide and ketolide antibiotics (Tripathi et al., 1998; Vimberg 
et al., 2004). A random five-codon gene library was also used to isolate mini-
genes whose expression causes cell growth arrest (Tenson et al., 1999). More-
over, it has been demonstrated that peptides with antimicrobial activity, 20 
amino acids long, can be screened effectively from a random genetic library by 
in vivo expression (Choi et al., 2002). 
We generated a plasmid library in order to find cis-acting regulatory se-
quences that suppress β-lactamase expression in response to chemically diverse 
compounds. Our library contained an SD element, initiation codon and 21 
random nucleotides in front of the β-lactamase ORF. In theory, the number of 
all possible RNA sequences coded by a random sequence of 21 nucleotides is 
421 (more than 1012) and the number of possible heptapeptide sequences is 207 
(1.28 × 109). Our initial library contained 106 clones which represents only a 
small fraction of all possible sequence variants. Nevertheless, we expected that 
if strong sequence preference patterns are involved, they would be revealed.  
 
Site-directed mutagenesis 
To investigate the functional importance of ribosomal protection protein Tet(O) 
domain 4 loops, a series of Tet(O) mutant variants were generated by site-
directed mutagenesis. This method is a fundamental tool in molecular biology 
that is often used to elucidate the function of a gene or protein. Several 
techniques have been developed to introduce substitutions, deletions or 
insertions into DNA. Older techniques that are based on extension of a single 
mutation-containing primer are now rarely used as they comprise multiple steps 
and require selection of the mutant products (reviwed in Braman, 2002). Site-
directed mutagenesis can also be performed using PCR and primers con-
taining the desired change. During PCR, the primer sequence replaces the 
original sequence, but the changes should be small enough to allow the primer 
to anneal to the target (Mullis and Faloona, 1987). 
Site-directed mutagenesis by overlap extension employs two rounds of PCR 
and nested primers (Ho et al., 1989; Lee et al., 2010). Figure 16 demonstrates 
the strategy for generating a deletion into tet(O) gene sequence. Primers B and 
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C were designed to position at either side of the region to be deleted. The first 
round of PCR used primers AB and CD to create two products. The ends of 
these products, created by primers B and C, were complementary to each other 
and enabled hybridization of the two fragments during the second round of 
PCR. As a result, the final RCR product containing the desired mutation was 
created using primers A and D. Substitution mutations were generated by 
employing internal primers B and C which contained the desired mutation in the 
overhang regions. The complementary ends of the first round PCR products 
were hybridized and the next PCR created the final product bearing the desired 
insertion. 
 
 
Figure 16. Deletion mutagenesis by overlap extension PCR (explanation in text). 
 
Antimicrobial susceptibility testing 
Antimicrobial activity of antibiotics is usually assessed by determination of the 
minimal inhibitory concentration (MIC) and minimal bactericidal concentration 
(MBC). MIC is defined as the lowest concentration of an antimicrobial that, 
under defined test conditions, will inhibit the visible growth of a microorganism 
(Wiegand et al., 2008). Most commonly used techniques to determine the MICs 
are agar dilution and broth dilution. Agar dilution involves the incorporation of 
different concentrations of an antimicrobial into a nutrient agar medium 
followed by the application of a standardized number of cells to the surface of 
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the agar plate. Broth dilution is performed using a series of dilutions of the anti-
microbial in liquid culture medium, to produce a range of concentrations in test 
tubes (macrodilution) or in a microtiter plate (microdilution). MIC is usually 
read after overnight incubation, but the time period can be extended for 
organisms which require prolonged incubation for growth (Andrews, 2001). 
The recommended bacterial inoculum size for broth dilution is 105 colony 
forming units per millilitre, whereas the appropriate cell number in agar dilution 
experiments is set at 104 colony forming units per spot (Wiegand et al., 2008). 
The MBC test can be viewed as an extension of an MIC test. MBC is the 
lowest concentration of an antimicrobial required to kill a particular micro-
organism. The simplest method for determining the MBC can be done by 
plating a subculture from antibiotic concentrations with no visible growth in the 
MIC test on to drug-free agar. This determines whether the bacteria have been 
inhibited from growing but are still viable, or whether they have been killed. An 
antibacterial is usually regarded as bactericidal if the MBC is not more than 
fourfold higher than the MIC (Levison, 2004). 
MBC tests are less clinically relevant. MICs, on the other hand, are routinely 
determined in diagnostic laboratories to confirm resistance. MIC measurement 
has also become a standard procedure to evaluate the in vitro activity of new 
antimicrobials. Therefore, I determined MIC values of E. coli and yeast to G1 
compound by broth dilution method. The results characterize the antimicrobial 
potency of G1. 
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4. RESULTS AND DISCUSSION 
4.1. Selection of ligand-dependent cis-acting  
regulatory sequences (I) 
Protein synthesis in living cells is a complex and highly regulated process. Most 
of translation regulation occurs at the level of translation initiation and is 
mediated by small trans-acting proteins or RNA-molecules (reviewed in 
Babitzke et al., 2009; Jackson et al., 2010). However, several studies have 
identified naturally existing nascent peptides that act in cis via inhibiting their 
own translation and can induce programmed translational arrest (Lovett and 
Rogers, 1996). In some cases, ribosome stalling occurs during translation of 
short upstream ORFs, so-called leader peptides. Translational arrest represents 
one possibility for regulating expression of downstream genes (Wilson et al., 
2016).  
Ribosome stalling on the mRNA is either dependent or independent from the 
binding of an effector molecule (an antibiotic, an amino acid, etc) to the ribo-
some (Ramu et al., 2009). Previous studies have identified peptide sequences 
that induce ribosome stalling in response to erythromycin (Weisblum, 1995b), 
chloramphenicol (Lovett and Rogers, 1996), tryptophan (Gong et al., 2001), 
arginine (Delbecq et al., 2000) and polyamides (Law et al., 2001, Raney et al., 
2002). A well-studied example of effector-independent ribosome pausing is 
regulation of expression of sec operon in E. coli (Nakatogawa and Ito, 2002). 
Many naturally occurring cis-acting sequences are involved in regulation of 
gene expression. In some cases, they control synthesis of enzymes that confer 
resistance to antibiotics, such as macrolides or chloramphenicol. A prominent 
example of ribosome stalling-mediated gene expression is the regulation of 
ermC gene expression. First described in Staphylococcus aureus (Weisblum et 
al., 1971), ermC was later found also in other bacteria including Bacillus (Monod 
et al., 1986) and Neisseria (Roberts et al., 1999). ermC encodes a methyltrans-
ferase which mono- or di-methylates A2058 residue in 23S rRNA. Methylation 
of A2058 confers so-called MLSB resistance that interferes with binding of 
macrolide, lincosamide and streptogramin B antibiotics to the ribosome 
(Weisblum, 1995a). Expression of ermC is controlled by ermCL, a 19-codon 
ORF that is located 60 bp upstream of ermC (Gryczan et al., 1980). Both ermCL 
and ermC are transcribed as a single mRNA. Under normal conditions, 
translation of ermCL is enabled, while the ribosome binding site of ermC is 
sequestered in the secondary structure of mRNA. Subinhibitory concentrations 
of an inducing drug (erythromycin or similar macrolides) cause ribosome 
stalling on ermCL ORF, allowing mRNA to fold into alternative secondary 
structure. As a result, the RBS of ermC becomes exposed for the ribosomes 
(Horinouchi and Weisblum, 1980).  
Results obtained so far suggest that ribosome stalling can be caused by a 
greater number of sequences and is more common event than initially believed. 
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However, the lack of a general selection method is a notable obstacle in finding 
new cis-acting regulatory sequences. Development and applying of an effective 
selection method would significantly accelerate the research by providing more 
sequences for analysis. Such selection method should be applicable for finding 
sequences that cause ribosome stalling in response to various compounds as 
most of described nascent peptide-mediated regulation mechanisms require the 
presence of a co-effector molecule (Tenson and Ehrenberg, 2002). 
Plasmid libraries provide a useful tool for selecting cis-acting peptide se-
quences that cause ribosome stalling in the presence or in the absence of a co-
effector. For instance, plasmid libraries have been successfully used for identi-
fying pentapeptides that modulate ribosome activity in response to various 
macrolide antibiotics (Tenson et al., 1997; Vimberg et al., 2004). 
Tanner and colleagues (2009) have selected stalling peptides from a plasmid 
library by using a modified tmRNA molecule. Their library was based on a gene 
encoding an inactive KanR protein that lacks 15 amino acids at its C-terminus. 
The C-terminal part of the gene was replaced by 18 random nucleotides (6 
random codons). When the ribosome reaches the end of truncated mRNA, it 
becomes arrested. Normally, tmRNA rescues stalled ribosome by entering the 
empty A-site and serving a new template for interrupted protein synthesis. 
tmRNA encodes a peptide tag that acts as a signal for cellular proteases. Tagged 
and released protein becomes a subject for degradation (Barends et al., 2011). 
However, the modified tmRNA used by Tanner’s group provides the missing  
C-terminal end of KanR instead of signal for proteolysis. Therefore, modified 
tmRNA helps to render cells resistant to kanamycin when ribosome stalling 
occurs during translation of six random C-terminal codons (Tanner et al., 2009). 
The described method enabled to identify some novel nascent peptides that 
induce ligand-independent ribosome stalling. 
In order to identify novel cis-acting sequences, we created a plasmid library 
in which β-lactamase gene was under the control of tac promoter. A region 
between the SD element and β-lactamase ORF contained 21 random nucleotides 
that were inserted by PCR. In the first step of selection, E. coli cells transformed 
with the plasmid library were grown in the presence of low concentration of 
ampicillin. This was done in order to exclude the clones exhibiting deficient  
β-lactamase activity from the further selection stages. Then, cells were washed 
and resuspended in fresh medium containing one of the compounds used for 
selection. These compounds of interest included macrolides erythromycin and 
troleandomycin, the PTC inhibitor chloramphenicol, a non-biological compound 
meta-toluate and a bacterial signal molecule homoserine lactone. After the cells 
had been grown in the presence of the chemical, ampicillin was added to the 
medium. We assumed that cells, in which the ribosomes become stalled in front 
of β-lactamase ORF, are sensitive to ampicillin and, thus, can be lysed with the 
antibiotic. The released plasmids were isolated from the medium by pre-
cipitation and used to transform new bacteria. The same selection cycle was 
repeated for two more rounds to enrich for sequences responding to the 
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chemical. Three rounds of selection were found to be optimal as additional 
rounds tended to limit the number of emerging sequences. 
Our selection method enabled to identify sequences in response to all tested 
compounds. An apparent conclusion is that cells became sensitive to ampicillin 
due to the presence of ribosome stalling sequence in front of β-lactamase ORF. 
However, an alternative explanation suggests that seven additional codons 
could disrupt the N-terminal region of β-lactamase thereby interfering with the 
stability or functional activity of the enzyme. To distinguish between these 
possibilities, we tested the functional activity of selected sequences in different 
reporter systems. We fused the sequences to β-galactosidase and GFP ORFs. 
Next, we measured the effect of sequences to the functionality of β-galacto-
sidase and GFP reporters in the presence of their corresponding compounds. 
The activity of β-galactosidase was determined by β-galactosidase assay (Miller, 
1992) and GFP expression was estimated by flow cytometry. We found that the 
sequences selected on erythromycin and chloramphenicol responded to their 
corresponding compounds in all of three tested expression systems (Reference I, 
Table I). Some troleandomycin peptides responded to troleandomycin in  
β-galactosidase context. However, none of troleandomycin sequences worked 
when inserted in front of GFP gene (Reference I, Figure 4), indicating that the 
reporter context may influence the specificity of the response. Sequences 
selected on meta-toluate and HSL displayed only weak activity in β-galacto-
sidase or GFP context. We speculate that the activity of stalling peptides can be 
affected by properties of corresponding mRNA. Variations in structures of 
translation initiation region together with mRNA secondary structure elements 
are known to play role in efficiency of translation (Geissmann et al., 2009; 
Kozak, 2005). Therefore, a disadvantage of our method is that many sequences, 
potentially able to cause ribosome stalling, may remain undiscovered, because 
they are not active in β-lactamase context. Similarly, as we observed, sequences 
that are active in front of β-lactamase may not function in other reporter 
systems. However, cis-acting sequences can retain their regulatory activity 
when inserted in the leader sequence of another gene. For instance, arginine-
sensitive leader peptide sequence of the yeast gene CPA1 can place another 
gene (namely, GCN4) under arginine repression (Delbecq et al., 1994). 
As mentioned, ermC leader peptide is one of the best-characterized cis-
acting regulators that respond to erythromycin (Dubnau, 1985; Mayford and 
Weisblum, 1990). We fused ermCL sequence to β-galactosidase ORF and 
compared the activities of sequences selected on erythromycin with the activity 
of ermCL using the β-galactosidase assay. We noticed that the activity of 
ermCL peptide was only a little higher than the activities of peptides selected 
from our library (Reference I, Figure 3). This result is somewhat surprising, as 
previous studies have reported stronger ermCL effects (Mayford and Weisblum, 
1990). One may assume that stalling sequences need a specific context for 
showing their maximum activity. 
Comparison of selected sequences did not reveal any recognizable consensus 
motif neither at the mRNA nor at the peptide level. This result is not surprising 
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as previous studies have also failed in finding common sequence motifs 
(reviewed in Ramu et al., 2009). Moreover, mutation of a single amino acid of 
the nascent chain could be sufficient to not only broaden or narrow the spectrum 
of molecules, which can elicit the functional response of the ribosome, but also 
switch the specificity of recognition from one chemical to another (Gupta et al., 
2016). It is possible that certain sequence rules exist, but their discovery is 
hampered due to only limited number of sequences available. Thus, it is likely 
that increasing the number of clones in the initial library could lead to identifi-
cation of more sequences thus facilitating the identification of consensus motifs. 
Despite of the lack of a common consensus motif, peptides selected on 
different chemicals demonstrated some trends in their amino acid composition. 
Peptides that were selected in the presence of erythromycin often contained 
leucine and serine (Reference I, Table I). Sequences selected on macrolide 
troleandomycin, a synthetic derivative of oleandomycin, were enriched in 
arginine. Chloramphenicol-dependent cis-acting sequences tended to contain 
glycine and sequences selected on HSL were rich in valine. Nevertheless, none 
of amino acids was prevalent in peptides selected on meta-toluate. 
The stalling sequences are thought to be active as peptides, i.e. they cause 
ribosome pausing while being translated. However, an alternative explanation to 
our results is that selected sequences are active as mRNA molecules. Selected 
mRNA sequences may interact with the compound that we use in selection and 
interfere with the translation process. In such manner, our selected sequences 
might act similarly to riboswitches. To examine the possibility that selected cis-
acting sequences inhibit protein synthesis on the level of mRNA, we substituted 
some codons within the sequences selected on erythromycin or chloramphenicol 
with synonymous ones. Thus, mRNA sequence was changed while peptide 
sequence remained invariant. Mutations in mRNA are likely to disrupt the 
possible ligand binding site. The activity of mutated peptides was measured in 
β-galactosidase assay. We did not observe significant difference between the 
activities of selected sequences and their mutated versions (Reference I, Figure 
1). We therefore conclude that at least the tested sequences (and most likely all 
sequences) are active as peptides. 
 
 
4.2. Mechanisms of ligand-dependent  
translational stalling (I) 
Formation of peptide bond between amino acids takes place in the peptidyl 
transferase center (PTC) of the ribosome. In order to exit the ribosome, the 
growing polypeptide chain must move through the tunnel that is located 
between the PTC and cytosol. The exit tunnel is 90–100 Å in length and 
approximately 15 Å in width, depending on the type of the ribosome (Bogdanov 
et al., 2010). Although the walls of tunnel are predominantly composed of 23S 
rRNA, ribosomal proteins L4 and L22 (L17 in eukaryotes) contribute in the 
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middle part where they render the tunnel as narrow as 10 Å in diameter (Nissen 
et al., 2000). 
Accumulating evidence suggests that the walls of exit tunnel are able to 
monitor amino acid sequence of the nascent polypeptide. The ribosomal tunnel 
plays a role in early protein folding events as well as in the regulation of 
translation (Wilson et al., 2016). Majority of rRNA nucleotide residues within 
the tunnel space are exposed to the growing polypeptide by their heterocyclic 
bases (Nissen et al., 2000). Thus, hydrophobic contacts as well as hydrogen 
bonds between the tunnel wall and nascent polypeptide are possible. Strong 
interactions between the polypeptide and the tunnel wall may result in trans-
lation arrest (Lovett and Rogers, 1996; Tenson and Ehrenberg, 2002). There are 
no large hydrophilic or hydrophobic regions within the tunnel. Nevertheless, 
movement of the growing polypeptide chain through the tunnel can be difficult 
if it contains blocks of basic arginine or lysine residues (Lu and Deutsch, 2008). 
We have isolated cis-acting peptides that cause ribosome stalling in response 
to three antibiotics, meta-toluate and HSL. Peptides selected on erythromycin 
tended to contain hydrophobic amino acids, such as leucine, glycine, valine and 
isoleucine. This is consistent with the fact that the critical C-terminal segments 
of many macrolide-regulated ORFs (ErmAL1, Erm39L, ErmCL) are hydrophobic 
(Mayford and Weisblum, 1990; Ramu et al., 2011). On the other hand, hydro-
philic amino acids such as aspartic acid and glutamic acid were very rarely 
components of selected peptides. This observation suggests that ribosome 
stalling in the presence of erythromycin preferably requires hydrophobic 
nascent peptides. To test this idea, we mutated the amino acid sequence of a 
peptide that exhibited the highest activity in β-galactosidase expression assay. 
Indeed, when the peptide was made more hydrophobic, its activity increased 
(Reference I, Figure 2). Consistently, insertion of hydrophilic amino acids into 
peptide decreased its activity. 
Previous studies have described a coincidentally discovered resistance 
mechanism to macrolides that is based on the activity of nascent peptides. These 
so-called macrolide resistance peptides are 4–6 amino acids in length and confer 
resistance to a ribosome on which the peptide is translated. During translation, 
the nascent peptide acts as a “bottle brush” that removes the bound macrolide 
molecule from the ribosome (Tenson and Mankin, 2001). It has been shown that 
the pentapeptide MRLFV can remove erythromycin from the ribosome. 
However, successful dissociation of erythromycin is dependent on the class 1 
release factor-mediated translation termination. Resistance pentapeptides do not 
work when termination does not take place and an additional amino acid is 
added to the peptide. In such case, further protein synthesis is inhibited due to 
erythromycin and the ribosome stalls (Lovmar et al., 2006). Selection experi-
ments have revealed peptide sequences that provide resistance to structurally 
different macrolides (Tenson et al., 1997; Vimberg et al., 2004). Interestingly, 
some similarities can be seen between macrolide resistance peptides and stalling 
peptides selected on macrolide antibiotics. For instance, minipeptides conferring 
resistance to erythromycin were found to be hydrophobic and enriched in leucine. 
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The same is also true for the cis-acting peptides causing ribosome stalling in 
response to erythromycin. These data suggest that the mechanism of peptide-
mediated macrolide resistance may be related to nascent peptide-mediated 
regulation of gene expression. 
 
 
4.3. Applications of cis-acting sequences (I) 
Control over gene activity is one of the most important mainstays in synthetic 
biology. Many attempts have been made to generate various gene expression 
systems as they provide a powerful tool for applied biotechnology (transgenic 
disease models, drug discovery, etc) as well as for basic gene function research 
(May et al., 2006). In most cases, essential components of successful eukaryotic 
expression platforms (Cre/lox, Flp/FRT, Tet-systems) are derived from 
prokaryotes (Sauer and Henderson, 1989; O’Gorman et al., 1991; Gossen and 
Bujard, 1992). Gene activity in different expression systems is often regulated 
by co-effector molecules, such as antibiotics (Fussenegger et al., 2000; Weber 
et al., 2002), hormones (Braselmann et al., 1993), quorum sensing molecules 
(Neddermann et al., 2003) or vitamins (Weber et al., 2007). In addition, tem-
perature-sensitive DNA expression systems have been generated (Boorsma et 
al., 2000). The systems are designed to be either inducible (ON-type) or 
repressible (OFF-type), i.e. gene expression occurs either in the presence or in 
the absence of an inducer, respectively.  
In all of mentioned expression systems, gene activity is regulated at the level 
of transcription. However, translationally regulated systems can have advantages 
under circumstances where other expression platforms cannot be used. For 
instance, stalling sequences could be applied as cis-regulatory elements for gene 
therapy vectors that are based on RNA viruses (reviewed in Gould and Favorov, 
2003; Yamanaka, 2004). Another restriction of transcriptionally regulated 
systems is the fact that they often contain elements of great size, which makes 
them inappropriate for small viral vectors. 
We have shown that our selection method is suitable for finding peptides 
that cause ribosome stalling in the presence of certain ligands. Our findings may 
have important biotechnological implications. In theory, cis-acting nascent 
peptides can be used for designing novel gene expression systems that are 
regulated at the level of translation. Control of gene activity in such systems 
would be based on interaction between the co-effector molecule and a nascent 
peptide in the ribosome. In ligand-dependent translational systems, expression 
of a gene of interest can be either repressed or induced. Translation of a gene 
can be repressed when this gene is preceded by a regulatory upstream ORF 
containing a stalling sequence. Alternatively, for inducible regulation, an ORF 
containing a stalling sequence can be inserted upstream of an ORF encoding a 
specific repressor protein. In the presence of a co-effector, expression of a 
repressor is inhibited thereby enabling translation of a desired gene.  
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Translational arrest can occur in response to chemically miscellaneous com-
pounds, but not every compound is appropriate for the use in living systems. 
Antibiotics are harmful to bacteria and the use of cis-acting sequences that 
response to erythromycin, troleandomycin and chloramphenicol in prokaryotic 
systems is therefore complicated. Nevertheless, we have successfully selected 
cis-acting sequences that respond on chemically diverse molecules and by 
applying our method, sequences that act in the presence of non-toxic com-
pounds could be identified. The suitable ligands should be cell permeable 
molecules that are not subjects for cellular metabolism. 
Recognition of a stalling sequence can evidently happen in a number of 
modes. Despite of generally conserved nature of the ribosome, there are species-
specific significant variations in tunnel wall properties (Vazquez-Laslop and 
Mankin, 2011). It must be pointed out that our stalling peptides were isolated 
using the prokaryotic selection system. Therefore, before applying in eukaryotic 
system, it is critical to test their ability to stall a eukaryotic ribosome.  
The cis-acting regulatory sequences that respond to diverse chemicals are 
already extensively used in molecular biology studies. For instance, ErmCL 
peptides were successfully used in cryo-electron microscopy reconstruction of 
the ribosome protection protein Tet(M) in complex with a translating ribosome 
(Arenz et al., 2015). Our method can be considered as a promising tool for 
finding new cis-acting regulatory sequences. Applying the method on a larger 
scale, by selecting and comparing an extended set of sequences, might lead to 
identification of yet unknown sequence rules and better understanding of 
mechanisms of translational arrest. This in turn could facilitate the development 
of novel biological sensing and expression systems or synthetic riboswitches. In 
these expression systems, gene expression would be controlled by interaction 
between the ribosome, cis-acting sequences and small ligand molecules.  
 
4.4. The role of domain IV of ribosomal protection protein 
Tet(O) in tetracycline resistance (II) 
Tetracyclines are broad-spectrum antibiotics that inhibit protein synthesis by 
interfering with delivery of aa-tRNAs to the A-site (Wilson, 2014). Although 
tetracycline has been shown to bind to multiple sites on the 30S ribosomal 
subunit, only one binding site has been directly associated with its antimicrobial 
effect. This primary binding site is located in close vicinity of the A-site codon, 
in a crevice between the head and platform of the small ribosomal subunit 
(Brodersen et al., 2000; Pioletti et al., 2001).  
Resistance to tetracycline can be achieved via active efflux (Chopra and 
Roberts, 2001), enzymatic inactivation of the drug (Volkers et al., 2011), muta-
tions in 16S rRNA (Ross et al., 1998) or by ribosomal protection (Connell et al., 
2003a). Ribosomal protection proteins (RPPs) represent a unique resistance 
mechanism that was first identified in Streptococcus faecalis (Burdett, 1986). 
To date, 12 RPPs have been reported and they are widespread among both 
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Gram-negative and Gram-positive bacteria. RPPs can confer resistance to 
tetracycline and many of its derivatives by removing the drug from the drug-
stalled ribosome in a GTP-dependent manner (Burdett, 1996; Trieber et al., 
1998). However, the molecular details of RPP-mediated resistance started to 
become evident only recently with the appearance of high-resolution cryo-EM 
structures. 
In 2001, a cryo-EM structure of Tet(O) was published with a density map at 
a resolution of 7.2 Å. It revealed that Tet(O) has a similar shape as elongation 
factor EF-G (Spahn et al., 2001). RPPs and EF-G are known to share a high 
degree of sequence homology (Thakor et al., 2008; Sanchez-Pescador et al., 
1988). Based on the X-ray structure of EF-G, our workgroup generated a cryo-
EM density map at 9.6 Å resolution for the complex of Tet(O) from Campylo-
bacter jejuni bound with the E. coli 70S ribosome in the presence of non-
hydrolysable GTP analogue GDPNP. Guided by the density map, an atomic 
model of Tet(O) was built and interactions between Tet(O) and the ribosome 
were identified (Reference II, Figure 3). 
Our molecular model is consistent with the previously obtained cryo-EM 
structure of Tet(M):70S ribosome at 7.2 Å resolution (Donhofer et al., 2012). 
The binding site of RPP is located within the intersubunit cavity of the 
ribosome. In this position, RPP forms interactions with both small and large 
ribosomal subunit. The overall localization of RPP on the ribosome is similar to 
that observed for EF-Tu:tRNA complex and overlaps with the anticodon stem-
loop of A-tRNA (Donhofer et al., 2012; Spahn et al., 2001).  
RPPs are composed of five structural domains. Domain IV consists of a 
four-stranded β-sheet and two α-helices (Donhofer et al., 2012). These moieties 
are connected by three characteristic loops (the 465-, 507- and the 438 loop) 
that are located at the tip of domain IV (Figure 17) and extend into the head-
platform crevice of 30S subunit (Reference II, Figure 3). The location and 
remarkable expansion of the three loops suggests that they might be critical for 
removal of tetracycline molecule from the ribosome. Previous work established 
that domain IV interacts with helix 34 of 16S rRNA adjacent to the tetracycline 
binding site and protects residues C1214 and C1054 within helix 34 from 
chemical modification (Connell et al., 2002). It was suggested that Tet(O) re-
moves tetracycline from the ribosome indirectly via inducing conformational 
changes within helix 34 (Spahn et al., 2001; Connell et al., 2002; Connell et al., 
2003b). However, a recent study demonstrated that Tet(M), a paralogue of 
Tet(O), removes tetracycline from the ribosome via direct mechanism of action. 
Domain IV of Tet(M) was shown to interact with the tetracycline binding site, 
indicating that Tet(M) can disrupt the stacking interaction between the aromatic 
ring D of tetracycline and C1054 (Donhofer et al., 2012). 
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Figure 17. The model structure of Tet(O) with domain IV rendered in teal. Loops 438, 
465 and 507 are shown in orange. 
 
We performed a mutational analysis in order to evaluate the importance of the 
three loops of Tet(O) domain IV in expelling the antibiotic from the ribosome. 
We introduced a series of substitution and deletion mutations into regions that 
are either directly or closely involved in the interactions in the tetracycline-bin-
ding site. Plasmids bearing either C. jejuni wild-type Tet(O) or one of mutant 
variants were transformed into E. coli strain BW 25993 and the change in tetra-
cycline susceptibility was measured by minimum inhibitory concentration (MIC) 
assay (Reference II, Figure 4c and Table 1). 
The atomic model suggests that tetracycline and Tet(O) cannot co-exist on 
the same ribosomal complex as there would be a clash between the 507-loop of 
Tet(O) and the drug. Therefore, it was expected that mutation of 507-loop might 
have a crucial influence on the release of tetracycline from the ribosome. Indeed, 
substitution mutation Y507A resulted in 83% loss of Tet(O) activity when 
compared to the wild-type (Reference II, Table 1). Moreover, replacement 
YSP507-509G completely abolished Tet(O) activity (Reference II, Table 1). 
Members of Daniel Wilson’s lab have performed a similar alanine-scanning 
mutagenesis to investigate the role of Tet(M) in tetracycline release (Donhofer 
et al., 2012). Consistent with our result, they observed that double and triple 
mutations within the corresponding loop rendered Tet(M) inactive. Surprisingly, 
no single alanine substitution within the loop exhibited a significant effect of 
Tet(M) to confer tetracycline resistance (Donhofer et al., 2012). Our results 
show that the 507-loop is absolutely necessary for RPP-mediated tetracycline 
resistance. Interestingly enough, sequence alignment of translational GTPases 
belonging to tetracycline-family revealed that the three loops are not very 
strongly conserved within the Tet family (Reference II, Figure 4a). This finding 
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along with experimental data suggested that the loops of domain IV can 
maintain their functionality in spite of a certain amount of sequence variability. 
The 465-loop of Tet(O) extends into pocket near nucleotides 1051 and 1209 
of 16S rRNA helix 34 (Reference II, Figure 3). The primary binding site of 
tetracycline is located in the immediate vicinity of this region and the drug 
forms hydrogen-bond interactions with the nucleotides in helix 34 (Brodersen et 
al., 2000; Jenner et al., 2013). Our atomic model suggested that the 465-loop 
can reorient the nucleotides 1051–1054 in helix 34 thus ruining interactions 
between tetracycline and 16S rRNA. In accordance with that, replacement 
LGY466-468G in the 465-loop resulted in complete loss of Tet(O) activity 
(Reference II, Table 1). Point mutations L466A and S472A resulted in 33% and 
76% loss in Tet(O) activity, respectively. These observations emphasized the 
importance of 465-loop to the functionality of Tet(O) and were consistent with 
our structural data. Contrary to our conclusion, experiments with Tet(M) mutant 
variants have suggested that the 507-loop rather than the 465-loop alters the 
conformation of helix 34 to chase tetracycline from the ribosome (Donhofer et 
al., 2012). This indicates that Tet(O)- and Tet(M)-mediated mechanisms possess 
small differences at the molecular level.  
Finally we examined the influence of the 438-loop on Tet(O) functionality. 
Substitution VPP436-438G abolished Tet(O) activity and a single substitution 
P438A resulted in 83% reduction of Tet(O) activity (Reference II, Table 1). 
These strong effects were rather surprising as according to the atomic model, 
the 438-loop lacks a direct contact with tetracycline molecule. We proposed that 
the 438-loop together with 16S rRNA nucleotides 966 and 1196 forms a struc-
tural corridor, which acts as the pathway for the release of tetracycline from the 
ribosome. 
In combination with the structural data, our mutational analysis enabled a 
first insight into molecular mechanism of Tet(O)-mediated tetracycline resistance. 
According to our model, the 465-loop distorts the backbone shape of the 16S 
rRNA at the tetracycline-binding site. This in turn weakens interaction between 
the tetracycline molecule and 16S rRNA and enables the 507-loop to directly 
dislodge tetracycline from the ribosome. The 438-loop along with nucleotides 
966 and 1196 should form a corridor allowing tetracycline to exit. 
Recently, Daniel Wilson’ group published a paper in which they presented a 
Tet(M):70S ribosome complex at a resolution of 3.9 Å (Arenz et al., 2015). 
They demonstrated that Pro509 at the tip of 507-loop, rather than previously 
reported Y506 and Y507, overlaps with ring D of ribosome-bound tetracycline. 
Therefore, Pro509 is directly involved in dislodging tetracycline from the ribo-
some. Pro509 is identical in all available RPP sequences. New model suggests 
that the role of Y506 and Y507 is to stabilize conformation of the 507-loop in 
Tet(M) (Arenz et al., 2015). It is very probable that the details and mechanism 
of action are conserved for other RPPs. Our results support this idea as muta-
tions in positions 507 and 507–509 of domain IV strongly inhibited Tet(O) 
activity.  
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4.5. Stability and reactivity of G1 in biological  
culture-media (III) 
2-Bromo-5-(2-bromo-2-nitrovinyl)furan, also known as G1 or Furvina®, is a 
synthetic nitrovinylfuran (Drobnica and Sturdik, 1980). This compound is un-
stable in aqueous media and has been shown to degrade into 5-bromo-2-fural-
dehyde and 2-bromo-5-(2-nitrovinyl)furan (Castro-Hermida et al., 2004; Scholz 
et al., 2013). The presence of thiol groups in medium stimulates degradation as 
G1 is a thiolreactive compound like other nitrovinylfurans (Balaz et al., 1982; 
Scholz et al., 2013). Our interest to decomposition of G1 arose with the random 
observation that the yellow colour of G1 solution vanishes rapidly when some 
drops of cysteine hydrochloride are added to the mixture. This discovery gave 
an idea that decomposition of G1 can be characterized using colorimetric 
methods. 
G1 has the absorption maximum at 390 nm. We dissolved G1 in DMSO and 
measured its half-life in media that are often used in biological assays. Among 
these selected media, M9 minimal medium does not contain thiol groups. On 
the other hand, bacterial growth medium CAMHB and mammalian cell culture 
medium IMDM contain thiols at unknown concentrations. As expected, G1 was 
more stable in M9 medium (half-life 58 minutes), while decomposition occurred 
faster in thiole-containing CAMHB and IMDM (half-lives 6 and 11 minutes, 
respectively; Reference III, Figure S1 in the Supplemental material). 
In order to elucidate G1 decomposition in the presence of thiols, we dissolved 
G1 in M9 minimal medium at the concentration of 16 µg/ml (0.054 mM). To this 
solution we added cysteine hydrochloride monohydrate to the final concentration 
of 20 µg/ml (0.114 mM), 50 µg/ml (0.285 mM), 100 µg/ml (0.569 mM) or 
500 µg/ml (2.85 mM). We observed that in the presence of cysteine hydro-
chloride, the adsorption maximum peak shifted from 390 nm to 372 nm (Refe-
rence III, Figure 2a). We hypothesized that the change in spectrum is caused by 
conversion of G1 into new yet unknown compound. Increasing of cysteine con-
centration reduced adsorbance at 372 nm but a large molar excess of cysteine 
was needed for disappearance of adsorbance maximum between 350–400 nm. 
In addition, we found that G1 decomposition in the presence of thiols depends 
on the pH of the medium. The reaction rate increased at higher pH values 
(Reference III, Figure 2c). This is consistent with a previous finding (Sturdik et 
al., 1979). 
The details of G1 decomposition along with the structures of breakdown 
products were characterized by NMR and HPLC analysis. We found that in the 
presence of cysteine hydrochloride, G1 is converted to 2-bromo-5-(2-nitrovinyl)-
furan (Reference III, Figure 3a). Conversion occurs over an unstable inter-
mediate compound that cannot be detected in our colorimetric measurements as 
its maximum absorbance is in ultraviolet area. On the other hand, 2-bromo-5-(2-
nitrovinyl)furan has a maximum absorbance at 372 nm and is visible in colori-
metric measurements. By increasing the concentration of cysteine hydro-
chloride, 2-bromo-5-(2-nitrovinyl)furan converts further into covalently bonded 
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cysteine conjugate. In the presence of remaining cysteine this conjugate trans-
forms back to 2-bromo-5-(2-nitrovinyl)furan. In the course of hours 2-bromo-5-
(2-nitrovinyl)furan was finally found to decompose irreversibly to 5-bromo-2-
furaldehyde. NMR spectrocopy also revealed that reduced cysteine molecules 
that form during G1 decomposition react with each other to produce cystine. 
This explains why disappearance of absorbance maximum between 350–400 nm 
requires large amount of cysteine.  
The exact mechanism of action of G1 has been a matter of debate. One study 
demonstrated that G1 targets the P-site of small ribosomal subunit and inhibits 
protein synthesis in vitro by interfering with the binding of fMet-tRNA during 
30S initiation complex formation (Fabbretti et al., 2012). Another work indi-
cated that G1 is reactive towards cysteine residues in proteins, thereby inhi-
biting their functional activity (Scholz et al., 2013). Our current experimental 
finding demonstrates that activity of G1 is rather based on non-specific 
modification of thiol groups. Our data together with other reports indicate that 
the same mode of action is shared by all vinylfurans (Scholz et al., 2013; 
Sturdik et al., 1979).  
 
 
4.6. Antimicrobial properties of nitrovinylfuran  
derivative G1 (III) 
G1 possesses antimicrobial activity against Gram-positive and Gram-negative 
bacteria, yeasts, dermatophytes and filamentous fungi (Blondeau et al., 1999). 
As presented above, G1 is unstable in biological culture media and inter-
converts into an array of reaction products. It has been shown that at least some 
of these decomposition products exhibit antibacterial or cytotoxic effects 
(Scholz et al., 2013). Standard tests for measuring antimicrobial activity, such 
as minimum inhibitory concentration, are endpoint measurements and score the 
compound’s effect usually 24–72 h after its application. Such tests do not 
explain, how much of the antibacterial effects are attributed to the compound 
itself and how much are due to its breakdown products. To make a distinction 
between the antimicrobial properties of G1 and its conversion products, we 
added G1 to different growth media and scored MIC after preincubation of 
these mixtures for 5, 60 or 120 minutes prior to inoculation. The tested micro-
organisms included two Escherichia coli strains and a clinically relevant yeast 
Candida albicans. We found that G1 has much lower MIC in cysteine-free M9 
minimal medium when compared to CAMHB medium (Reference III, Table 1). 
The antimicrobial potency of G1 was considerably reduced in both M9 and 
CAMHB when cysteine hydrochloride (final concentration of 100 µg/ml) was 
added to media. However, the antimicrobial properties of the compound were 
not lost even after 120 minutes of preincubation with cysteine indicating that 
the reaction products possess antimicrobial activity. 
Previous studies have tested in vitro activity of G1 against different organisms 
using microbroth dilution (Blondeau et al., 1999). As mentioned before, this 
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simple test is not a suitable method for studying unstable compounds such as 
G1. Our aim was to delineate the bacteriostatic and bactericidal effects of G1. 
For this, we performed a time-dependent killing experiment with different drug 
concentrations in CAMHB medium. We added G1 to log-phase bacteria at the 
concentrations corresponding to 1-, 2-, 4-, and 10-fold MIC value (8, 16, 32, 
and 80 µg/ml respectively). Samples were collected before addition of G1 and 
during a 5-hour growth period. Samples were serially diluted on microwell plate 
and drop-plated on LB agar. After 20 hours of incubation we determined the 
number of viable bacteria. We found that at the G1 concentration of 8 µg/ml, 
bacterial growth decreased but did not stop completely (Reference III, Figure 4a 
and 4b). At 16 µg/ml, the drug was bacteriostatic. Higher G1 concentrations 
were bactericidal to proliferating E. coli culture. 
Most antibiotics are ineffective against non-growing bacteria. In addition, 
the antimicrobial efficiency of antibiotics depends on the culture density of the 
targeted microbe (Udekwu et al., 2009). The reactivity of G1 against thiol groups 
is rather nonselective. Therefore we tested the activity of G1 on non-growing 
cells. Stationary phase E. coli cells were collected by centrifugation and the 
growth medium was filter-sterilized. Bacteria were resuspended in the con-
ditioned medium. Simultaneously, 10-, 100-, and 1000-fold dilutions of bacteria 
were prepared. All cultures were grown in the presence of different G1 
concentrations. Samples were collected before adding G1 and after five hours of 
incubation with the compound. All samples were washed, serially diluted on 
microwell plate and drop-plated on LB agar. We found that the effect of G1 on 
stationary phase cells depends on the concentration of the drug and also on the 
concentration of bacteria (Reference III, Figure 5). Efficient killing of stationary 
phase cells was achieved only with the highest tested G1 concentration 
(80 µg/ml). Moreover, at least 100-fold dilution of bacteria (corresponding to 
107 CFU/ml) was required for killing. This result shows that killing of the non-
growing E. coli is considerably less efficient than killing of proliferating bacteria. 
Thus, G1 cannot be regarded as a powerful drug against non-growing pathogens. 
Despite of nonselective reactivity against thiols, the antimicrobial activity of G1 
depends on bacterial growth stage. 
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5. CONCLUSIONS 
Reference I 
We have developed a method for identifying cis-acting sequences that suppress 
expression of a marker gene in response to diverse chemicals. At least the 
sequences selected on erythromycin act at the peptide level. We could not 
identify any consensus motifs. Activity of cis-acting sequences may depend on 
the genetic context. 
 
Reference II 
The three characteristic loops (465-, 507- and 438 loop) in domain IV of ribo-
somal protection protein Tet(O) are essential for Tet(O)-mediated tetracycline 
resistance. Two-amino-acid-long deletions in the tips of either loop 438, 465 or 
507 abolished Tet(O) activity. Single substitutions in the loops reduced Tet(O) 
activity in less extent, suggesting that a certain amount of sequence variability is 
tolerated in the loops.  
 
Reference III 
A nitrovinylfuran derivative G1 (or Furvina®) reacts rapidly in aqueous media 
with thiols such as cysteine and interconverts into an array of reaction products. 
The antimicrobial effect of G1 is a sum of its immediate reactivity and effects 
of its breakdown products. G1 is bacteriostatic for E. coli at the concentration of 
16 μg/ml, bactericidal at 32 μg/ml and inefficient against non-growing E. coli.  
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SUMMARY IN ESTONIAN 
Ribosoomiga seonduvad antibiootikumid ja 
antibiootikumiresistentsuse mehhanismid 
Antibiootikumid on nüüdisaegse meditsiini alustugi ja nende väärtust inimelude 
päästmisel peetakse mõõtmatuks. Üks tähtsamaid antibiootikumide sihtmärke 
on prokarüootne 70S ribosoom (Arenz ja Wilson, 2016; Poehlsgaard ja Douth-
waite, 2005; McCoy et al., 2011). Antibiootikumide abil on võimalik pärssida 
erinevaid valgusünteesi etappe (Wilson, 2009). Kuigi antibiootikumide mole-
kulid on ehituse poolest väga erinevad, seonduvad nad suhteliselt väheste ribo-
soomi piirkondadega. Tetratsükliinid ja aminoglükosiidid seonduvad ribosoomi 
30S alaühiku dekodeerivasse keskusesse ning takistavad mRNA poolt kodeeri-
tud geneetilise informatsiooni korrektset tõlgendamist. 50S alaühikul leidub 
kolm olulist antibiootikumide seondumiskohta (Wilson, 2011). Neist esimene 
on peptidüültransferaasne keskus. See on seondumiskohaks klooramfenikooli-
dele, oksasolidinoonidele ja tiamuliinile, mis pärsivad peptiidsideme moodus-
tumist. Teine tähtis 50S alaühikul paiknev antibiootikumide sihtmärk on pep-
tiidi väljumistunnel, kuhu seonduvad makroliidid, linkoosamiidid ja strepto-
gramiin B. Need ravimid takistavad sünteesitava peptiidahela kasvu ribosoomis. 
Mõned antibiootikumid, näiteks tiostreptoon, seonduvad ribosoomi GTPaasse 
regiooniga (Harms et al., 2008). 
Suur osa valgusünteesi regulatsioonist toimub initsiatsiooni tasemel ja vajab 
mitmesuguste valkude või RNA molekulide osavõttu (Babitzke et al., 2009; 
Jackson et al., 2010). Praeguseks on teada, et teatud juhtudel võib valgusüntees 
olla reguleeritud ka polüpeptiidahela poolt, mida ribosoom parajasti sünteesib. 
Teatud peptiidide transleerimine võib põhjustada ribosoomi seiskumist ja üht-
lasi blokeerida mRNA’l allavoolu paiknevate järjestuste translatsiooni (Lovett 
ja Rogers, 1996; Wilson, 2016). Mõned ribosoomi seiskumist põhjustavad pep-
tiidid toimivad iseseisvalt, kuid teatud juhtudel vajatakse seisaku toimumiseks 
väikese ligandmolekuli (antibiootikum, aminohape vms) juuresolekut (Ramu et 
al., 2009). Üks paremini uuritud looduslikke ligand-sõltuvalt ribosoomi seiska-
vaid peptiide on ErmCL, mis vajab funktsioneerimiseks erütromütsiini juures-
olekut. Kui keskkonnas on erütromütsiin, siis jääb ribosoom ErmCL mRNA’d 
transleerides seisma ja selle tulemusena saab võimalikuks allavoolu asetseva 
erütromütsiini resistentsust tagava geeni ekspressioon (Weisblum, 1995b). 
Tänaseks on teada mitmeid ribosoomi seisakut põhjustavaid peptiide 
(Weisblum, 1995b; Lovett ja Rogers, 1996; Gong et al., 2001; Delbecq et al., 
2000; Law et al., 2001). Huvitaval kombel pole neid võrreldes suudetud leida 
ühtset konsensusjärjestust. Samas võib oletada, et teatud reeglid on järjestuste 
hulgas siiski olemas ja nende tuvastamine on võimalik, kui analüüsida suuremat 
hulka peptiide. Seetõttu otsustasime töötada välja universaalse meetodi valgu-
sünteesi peatavate peptiide leidmiseks. Spetsiifiliselt soovisime leida järjestusi, 
mis peataksid ribosoomi kas erütromütsiini, troleandomütsiini, klooramfeni-
kooli, meta-toluaadi või homoseriinlaktooni juuresolekul. 
106 
Oma meetodit kasutades suutsime identifitseerida järjestused, mis spetsiifi-
liselt peatasid translatsiooni kõigi viie testitud ühendi juuresolekul. Meil ei 
õnnestunud peptiidide aminohappeliste järjestuste võrdlemisel tuvastada univer-
saalset konsensusjärjestust. See tulemus pole siiski üllatav, sest ka varasemad 
uuringud pole konsensusjärjestust avastanud. Siiski märkasime järjestuste 
võrdlemisel teatud seaduspärasusi. Erütromütsiini juuresolekul selekteeritud 
järjestused sisaldasid sageli seriini või leutsiini, troleandomütsiini juuresolekul 
tuvastatud järjestused arginiini ja klooramfenikoolile vastavad järjestused olid 
rikkad glütsiini poolest (artikkel I, tabel 1). Erütromütsiinile vastavad peptiidid 
kaldusid olema hüdrofoobsed, mis ühtib teiste autorite tulemustega. Kui me 
muteerisime peptiide veelgi hüdrofoobsemaks või hüdrofiilsemaks, siis nende 
aktiivsus vastavalt kasvas või vähenes (artikkel I, joonis 2). Seega vajab erütro-
mütsiini juuresolekul toimuv ribosoomi seisak eelistatult hüdrofoobset kasvavat 
peptiidi. Me ei välista, et meie meetodit laialdasemalt rakendades ja peptiidide 
valimit suurendades on võimalik tuvastada konkreetsemaid ribosoomi peatumist 
põhjustavaid järjestusmotiive. 
Teoreetiliselt on võimalik, et meie poolt selekteeritud järjestused ei mõjuta 
otseselt ribosoomi, vaid hoopis rikuvad ära β-laktamaasi struktuuri ja muudavad 
seetõttu rakud ampitsilliinile tundlikuks. Et seda võimalust kontrollida, mõõt-
sime järjestuste aktiivsust erinevates reportersüsteemides. Selleks paigutasime 
selekteeritud järjestused kas β-galaktosidaasi või GFP lugemisraami ette ja 
mõõtsime nende valkude ekspressioonitasemeid. Selgus, et ainult erütromütsiini 
ja klooramfenikooli juuresolekul selekteeritud peptiidid peatasid ribosoomi 
kõikides reportersüsteemides (artikkel I, joonised 3 ja 4). Me järeldame, et 
translatsioonilist seisakut põhjustavate peptiidide funktsionaalsus võib olla 
tugevasti mõjutatud mRNA kontekstist. 
Kontrollisime ka võimalust, et meie poolt selekteeritud järjestused ei funkt-
sioneeri mitte peptiidi vaid hoopis mRNA tasemel. Selekteeritud järjestus võiks 
toimida ribolülitina, sidudes selektsioonil kasutatavaid ühendeid ja pärssides 
valgusünteesi mRNA sekundaarstruktuuri muutumise kaudu. Selle võimaluse 
testimiseks asendasime mõned koodonid järjestustes sünonüümsete koodonitega 
ning mõõtsime nende funktsionaalsust β-galaktosidaasi reportersüsteemis. mRNA 
järjestuse muutumine rikub suure tõenäosusega võimaliku ligandi seondumis-
koha. Ilmnes, et sünonüümsed koodonid ei muutnud järjestuste funktsionaalsust 
(artikkel I, joonis 1). Seega on meie poolt testitud järjestused aktiivsed pep-
tiididena. 
Meie selektsioonimeetodi abil leitud järjestustel võib olla kasutusvõimalusi 
biotehnoloogia valdkondades. Üheks rakendusvõimaluseks võiksid olla uudsed 
Peptiidide selekteerimiseks konstrueerisime plasmiidse raamatukogu, kus 
ampitsilliinile resistentsust tagava β-laktamaasi lugemisraami ette oli sisestatud 
21 juhuslikku nukleotiidi. Selektsioon põhines eeldusel, et kui ribosoom peatub 
mRNA’l ligandmolekuli tõttu enne β-laktamaasi transleerimist, siis muutuvad 
rakud tundlikuks ampitsilliinile. Sellised rakud lüüsiti hiljem ampitsillini kasu-
tades ja nendes sisaldunud plasmiidid koguti sadestamise teel. 
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ekspressioonisüsteemid, kus geeniekspressioon on kontrollitud ribosoomi, 
kasvava polüpeptiidi ja spetsiifilise ligandmolekuli vahelise interaktsiooni kaudu. 
Käesoleva väitekirja teine publikatsioon on seotud antibiootikumiresistent-
suse valdkonnaga. Tavaliseks antibiootikumiresistentsuse tekkemehhanismiks 
on antibiootikumi märklaua modifitseerimine või mutatsioon, mistõttu ravim ei 
saa sihtmärgiga seonduda. Sageli sünteesivad bakterid ensüüme, mis modifit-
seerivad antibiootikumi molekule või lagundavad neid (Wright, 2005). Levinud 
on ka antibiootikumide rakust eemaldamine nende väljapumpamise teel 
(Schindler ja Kaatz, 2016; Blair et al., 2014). Sageli paiknevad resistentsust 
tagavad geenid mobiilsetel elementidel, mistõttu nad saavad horisontaalse 
geeniülekande teel kiiresti keskkonnas levida.  
Üheks unikaalseks nähtuseks on nn ribsoomi kaitsevalkude vahendusel toimuv 
resistentsusmehhanism, mis tagab resistentsuse tetratsükliinile (Taylor ja Chau, 
1996; Connell et al., 2003). Ribosoomi kaitsevalgud on levinud nii Gram-
negatiivsete kui ka Gram-positiivsete bakterite hulgas. Juba mõnda aega on 
teada, et kaitsevalgud on võimelised tetratsükliini seondumist ribosoomile takis-
tama, kuid mehhanismi üksikasjad on hakanud ilmema alles hiljuti tänu kõrg-
lahutus-mikroskoopia abil saadud struktuuride analüüsile (Donhofer et al., 
2012).  
Meie uuringute eesmärk oli heita valgust ribosoomi kaitsevalgu Tet(O)-
vahendatud resistentsusmehhanismile. Töö aluseks oli 9.6 Å lahutavusega 70S 
ribosoomi ja Tet(O) kompleksi atomaarne mudel. Struktuuri uuringud näitasid, 
et Tet(O) interakteerub nii väikese kui suure ribosoomi alaühikuga (artikkel II, 
joonis 3). Tet(O) koosneb viiest struktuursest domäänist. Domään IV tipus eris-
tuvad kolm iseloomulikku lingu (lingud 465, 438 ja 507) (artikkel II, joonis 4a). 
Struktuuriandmetele tuginedes püstitasime hüpoteesi, et need lingud on olulised 
tetratsükliini molekuli eemaldamisel ribosoomilt.  
Me tegime asendus- ja deletsioonimutatsioone Tet(O) neljanda domääni 
lingude regioonidesse, mis vastavalt atomaarsele mudelile interakteeruvad 
otseselt tetratsükliini seondumiskohaga või asuvad selle lähedal. Mutantsete ja 
metsik-tüüpi Tet(O) variantide analüüs näitas, et kõik kolm lingu on Tet(O) 
tööks hädavajalikud, sest mutatsioonid YSP507-509G (lingus 507), LGY466-
468G (lingus 465) ja VPP436-438G (lingus 438) kaotasid täielikult Tet(O) 
aktiivsuse. Ühe aminohappe asendused lingudes vähendasid Tet(O) aktiivsust, 
kuid ei kaotanud seda täielikult (artikkel II, tabel 1).  
Struktuursete uuringute ja mutatsioonanalüüsi tulemusi kõrvutades pakku-
sime välja mudeli Tet(O) vahendusel toimuva tetratsükliiniresistentsuse mehha-
nismi selgitamiseks. Meie arvates muudab Tet(O) ling 465 tetratsükliini seon-
dumiskoha juures 16S rRNA struktuuri. See nõrgendab interaktsiooni tetratsük-
liini molekuli ja 16S rRNA vahel ning võimaldab lingul 507 ravim ribosoomilt 
eemale tõugata. Me oletasime, et ling 438 koos 16S rRNA nukleotiididega 
moodustab kanali, mille kaudu tetratsükliin ribosoomilt lahkub. 
Väitekirja kolmas publikatsioon puudutab probleeme, mis on seotud uute 
turule ilmuvate antimikroobsete ainetega. Seoses multiresistentsete patogeenide 
levikuga on väga oluliseks muutunud uute antibiootikumide leidmine ja 
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kasutusele võtmine. Alates aastast 2000 on turule ilmunud 30 uut antibiooti-
kumi (Butler et al., 2017). Paljud ravimikandidaadid on sisenenud kliinilistesse 
katsetesse, kuid nende arendamine on erinevatel põhjustel pooleli jäänud. 
Samas leidub ka antimikroobseid aineid, mida kasutatakse meditsiinis, kuigi 
nende toimemehhanism pole veel selge. Üheks selliseks näiteks on nitrovinüül-
furaanide hulka kuuluv aine G1 ehk Furvina®, mida juba mõnda aega kasu-
tatakse Kuubal nahainfektsioonide ravis. 
On teada, et G1 laguneb vees ja tioolrühmi sisaldavate ühendite (näiteks 
tsüsteiini) olemasolu keskkonnas kiirendab seda protsessi. Me iseloomustasime 
G1 lagunemist spektrofotomeetriliselt, kasutades G1 neeldumisspektri maksi-
mumi (390 nm) muutumist G1 lagunemisel. Tsüsteiinhüdrokloriidi lisamisel G1 
lahusele toimus neeldumisspektri maksimumi kiire nihkumine ultravioleti suunas 
(artikkel III, joonis 2a). Reaktsiooni kiirus vähenes koos lahuse pH vähene-
misega (artikkel III, joonis 2c). G1 oli stabiilsem tsüsteiini mittesisaldavas M9 
minimaalsöötmes (poolestusaeg 58 minutit), kuid ühend lagunes kiiremini 
tioole sisaldavates CAMHB ja IMDM söötmetes (poolestusajad vastavalt 11 ja 
6 minutit) (artikkel III, joonis S1a lisamaterjalides). G1 lagunemise reaktsiooni-
skeem koos selle käigus tekkivate produktidega (artikkel III, joonis 3) selgitati 
välja tuumamagnetresonantsi ja kõrgefektiivse vedelikukromatograafia abil. 
On teada, et vähemalt mõned G1 lagunemise käigus tekkivatest produktidest 
säilitavad antimikroobse aktiivsuse (Scholz et al., 2013). Standardsed testid, 
näiteks tavaline MIC määramine, ei võimalda kindlaks teha, milline osa anti-
mikroobsest aktiivsusest tuleneb lagunemata ainest ja milline osa on põhjus-
tatud laguproduktidest. Selleks, et teha vahet G1 ja selle laguproduktide põhjus-
tatud antimikroobsetel efektidel, inkubeerisime uuritavat ainet enne MIC määra-
mist vedelsöötmes. Katsealusteks organismideks olid E. coli tüved BW25113 ja 
CFT073 ning pärm Candida albicans. Nagu võis ennustada, olid MIC väärtused 
tsüsteiinivabas söötmes väiksemad kui tioolrühmi sisaldavas söötmes (artikkel 
III, tabel 1). Kui lisasime söötmetele G1 lagunemist soodustavat tsüsteiin-
hüdrokloriidi (lõppkontsentratsioon 100 µg/ml), suurenesid MIC väärtused. 
Samas jäid G1 antimikroobsed omadused alles isegi pärast kahe tunni pikkust 
testile eelnenud inkubatsiooniaega. Me järeldame, et G1 aktiivsus on aine 
kohese reaktiivsuse ja laguproduktide antibakteriaalsete aktiivsuste summa. 
Soovides iseloomustada G1 toksilist mõju jagunevatele E. coli rakkudele, 
viisime läbi inhibitsioonikatse erinevate G1 kontsentratsioonidega. Leidsime, et 
G1 kontsentratsioon 8 µg/ml pidurdab bakterite kasvu, kuid ei peata seda täie-
likult. G1 kontsentratsioon 16 µg/ml mõjus rakkudele bakteriostaatiliselt ja 
kõrgemad kontsentratsioonid olid jagunevatele bakteritele bakteritsiidsed 
(artikkel III, joonised 4a ja 4b). Enamik antibiootikume takistavad vaid jagune-
vate bakterirakkude elutegevust ning on väheefektiivsed mittejagunevate 
rakkude vastu. Seetõttu uurisime G1 mõju statsionaarses faasis olevale E. coli 
rakukultuurile. Ilmnes, et mittejagunevate bakterite surmamine G1 abil on või-
malik, kuid selleks on vajalik kõrge G1 kontsentratsioon (80 µg/ml) ja vähemalt 
100-kordne bakterikultuuri lahjendamine (107 CFU/ml) (artikkel III, joonis 5). 
Seetõttu ei ole G1 efektiivne vahend mittejagunevate bakterite hävitamiseks. 
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